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ABSTRACT: The leishmaniases, caused by Leishmania species of
protozoan parasites, are neglected tropical diseases with millions of
cases worldwide. Current therapeutic approaches are limited by
toxicity, resistance, and cost. N-Myristoyltransferase (NMT), an
enzyme ubiquitous and essential in all eukaryotes, has been
validated via genetic and pharmacological methods as a promising
anti-leishmanial target. Here we describe a comprehensive
structure−activity relationship (SAR) study of a thienopyrimidine
series previously identified in a high-throughput screen against
Leishmania NMT, across 68 compounds in enzyme- and cell-based
assay formats. Using a chemical tagging target engagement
biomarker assay, we identify the first inhibitor in this series with
on-target NMT activity in leishmania parasites. Furthermore, crystal structure analyses of 12 derivatives in complex with Leishmania
major NMT revealed key factors important for future structure-guided optimization delivering IMP-105 (43), a compound with
modest activity against Leishmania donovani intracellular amastigotes and excellent selectivity (>660-fold) for Leishmania NMT over
human NMTs.
■ INTRODUCTION
Leishmaniases are diseases caused by protozoan parasites of
the genus Leishmania, which are transmitted to humans by
female sandflies of the genera Phlebotomus and Lutzomyia.
The clinical symptoms depend on the Leishmania species
involved and range from skin ulcers with permanent scars
(cutaneous leishmaniasis, CL) to swelling of the spleen and
liver (visceral leishmaniasis, VL). Leishmaniasis is distributed
worldwide: in 2015, 87 countries were considered endemic for
CL and 75 for VL, with 12−15 million people infected and up
to 30 000 deaths per year. Three hundred and fifty million
people are at risk of infection, and 1 million new cases occur
each year.1,2 Therapeutic approaches currently rely on four
main drugs: pentavalent antimonials (sodium stibogluconate,
SSG), miltefosine, amphotericin B, and paromomycin.
However, these drugs are limited by toxicity, cost, and
problematic treatment regimens, while drug resistance to SSG
has emerged in India.3 It is therefore important to develop
new drugs and therapeutic strategies for leishmaniases.
N-Myristoyltransferase (NMT) catalyzes the co-transla-
tional N-terminal myristoylation of a wide variety of proteins
in all eukaryotes. Recent studies identified NMT as a potential
target in drug discovery against diseases caused by fungi4,5 and
several protozoan parasites, including Plasmodium falcipa-
rum,6−9 Plasmodium vivax,10 and Trypanosoma brucei.11−13
Human (host) NMT has also been explored in viral
infections, including the common cold, poliovirus, foot-and-
mouth disease virus,14 enterovirus,15 and HIV,16 as well as in
cancer.17,18 In Leishmania, more than 30 high-confidence
NMT substrates have been identified, including a number of
proteins known to be critical for parasite function, suggesting
that NMT inhibition will have pleiotropic effects on the
parasite.19−24 The recent discovery and characterization of
DDD100097 have provided pharmacological validation of
NMT as a drug target in Leishmania;25 however, significant
challenges remain in translating its potent enzymatic activity
into in vivo activity while retaining selectivity over human
(Hs) NMTs. Despite DDD100097’s potency against the
Leishmania major (Lm) NMT and modest activity in
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intracellular amastigotes (EC50 2.4 μM), it only has a 10-fold
selectivity over HsNMTs.
We have previously reported peptidomimetic inhibitors of
LmNMT with sub-micromolar potency but minimal selectivity
over the two human NMTs 1 and 2,26 and a series of small-
molecule inhibitors targeting Leishmania donovani (Ld) NMT
from an initial benzo[b]thiophene scaffold, with optimized
analogues showing minimal host cell toxicity.27 However,
neither series inhibited intramacrophage L. donovani amasti-
gotes, the clinically relevant life stage of the parasite, implying
problems with stability or poor cellular uptake. In a previous
publication, we reported a high-throughput screen (HTS) of
Plasmodium falciparum (Pf) NMT and LdNMT against a
150 000 compound diversity set28 using a scintillation
proximity assay,29 identifying four series with good to
excellent selectivity against LdNMT over other NMTs,
based on aminoacylpyrrolidines, piperidinylindoles, thienopyr-
imidines, and biphenyl derivatives. Subsequently, we reported
the binding mode of all four series, elucidated by
cocrystallization with LmNMT,30 and these findings were
used to improve the potency of the aminoacylpyrrolidines and
piperidinylindoles in a structure-guided approach, leading to a
40-fold increased potency and good selectivity over
HsNMTs.31 However, due to poor cellular uptake, these
inhibitors also lacked cell-based activity.32
Here we report a comprehensive structure−activity relation-
ship (SAR) study of the thienopyrimidine series of potent
Leishmania NMT inhibitors, improving their selectivity over
human NMTs and identifying the first cell-active on-target
LdNMT inhibitors within this series.
■ RESULTS AND DISCUSSION
A more synthetically accessible analogue of the initial
thienopyrimidine HTS-hit, PF-00349412, resulted in a
recently published high-resolution crystal structure of
derivative 1 (also known as IMP-083) in complex with
LmNMT30 (Figure 1). Interestingly, the structure indicates
that two molecules occupy the peptide-binding groove. The
ligand proximal to myristoyl-CoA is proposed to be of higher
affinity due to its better fit to the electron density maps and its
lower mean atomic temperature (B) factor, while the distal
ligand is sometimes absent (Figures 1C and S2A). The basic
center in the N-methylpiperidine ring in 1 is predicted to be
92% protonated at pH 7.4, and in the crystal structure, this
group in the proximal ligand is protonated. It forms a
hydrogen bond with a water molecule, which in turn may
interact with LmNMT Tyr80, Tyr92, and Asn167, and ion-
pairing with the carboxylate of Leu421 is also observed.
Aromatic stacking interactions between LmNMT Tyr217 and
the thienopyrimidine system also contribute to the overall
recognition (Figure 1D). The N4 atom of the pyrimidine ring
additionally forms a direct hydrogen bond with Tyr345. The
third structural feature of the inhibitor, the nitrile group, is
surrounded by LmNMT Val81, Ala204, and Gly205. The
corresponding moiety in the distal ligand may form a
hydrogen bond with Asn376. Although the major interactions
between LmNMT and compound 1 are known, explaining the
17-fold selectivity (IC50 (HsNMT1)/IC50 (LdNMT)) of the
inhibitor (1) for Leishmania NMTs over the human enzyme is
not straightforward since all amino acid side chains involved
in significant interactions are conserved in human NMT. We
hypothesized that conformational preferences in LdNMT and
LmNMT Tyr217 compared with that of the equivalent
HsNMT1 residue might cause the observed potency differ-
ences.9,30
■ SYNTHESIS
In this SAR study, variation in the ligand core and
substitutions at the C2, C4, C6, and C7 positions were all of
interest (Figure 2B). The syntheses of lead ligand 1 and
analogues were designed to allow variation at each of these
positions, exploiting the ability to selectively displace the 4-
chloro substituent of 2,4-dichloropyrimidines to thieno[3,2-
d]pyrimidines and other fused heterocyclic cores of interest.33
After synthesis of the heterocyclic core according to literature
methods, the C4 substituent was selectively incorporated by 4-
chloro displacement using stoichiometric quantities of the
appropriate amine and controlled temperatures. Displacement
at the 2-chloro position to generate C2 analogues, such as 2,
was then achieved using an excess of a second amine and
higher reaction temperatures, often under microwave irradi-
ation (Scheme 1).34
However, it was not possible to use a one-step 2-chloro
displacement to access compound 1 or later analogues such as
3, 10−13, or 15−16, either due to the presence of two
possible nucleophilic centers in the amine reagent, e.g., N-
methylpiperidin-4-amine for analogue 10, or limited commer-
cial availability. Attempts to synthesize des-methyl derivatives,
Figure 1. Binding pocket of compound 1 in LmNMT. (A) Ribbon rendering of LmNMT color ramped from amino (blue) to carboxy (red)
terminus. The atoms of the myristoyl-CoA and 1 ligands are shown in space-filling representations and colored by atom types C (gray), O (red),
N (blue), P (magenta), and S (yellow). (B) Structure of 1 (also known as IMP-083). (C) Cylinder rendering of the ligands emphasizing the
proximal and distal binding sites for a pair of molecules of 1, which pack against one another. (D) Binding pocket for 1 showing the Cα and side
chains of 1-interacting residues together with the C-terminal residue Leu421 whose α-carboxylate makes an ion-pairing interaction with the
tertiary amino group of the proximal ligand. Water molecules in the neighborhood of 1 are shown as red spheres, and polar protein−ligand
interactions are denoted by dashed lines. PDB ID: 4cgo.
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for example, using 4-amino-N-methylpiperidine, failed due to
a competing demethylation/displacement reaction that led to
an inseparable mix of products.35 Instead, the additional basic
center was protected using a more sterically hindering N-
benzyl group during the displacement reaction and then
deprotected in a two-step process, generally using 1-
chloroethyl chloroformate and methanol.36 The resulting
secondary amine could be derivatized using reductive
amination to give the desired products. This methodology
was successfully applied to generate compound 1 and also
analogues with quinazoline cores (3) or molecules containing
linear- (11, 15), pyrrolidine- (26, 52, 53), or piperidine-based
amines at the C2 position (12, 13). Detailed procedures for
the different cores and scaffolds are given in the Supporting
Information.
■ ACTIVITY
A fluorogenic assay was used to analyze the potency of all
inhibitors against Ld, Lm NMTs, and HsNMT1.37 The assay
quantifies the amount of coenzyme A liberated during the acyl
transfer reaction using the fluorogenic thiol-reactive dye 7-
diethylamino-3-(4-maleimido-phenyl)-4-methylcoumarin
(CPM). Initial analysis of a selection of 11 compounds against
both Leishmania NMTs revealed a strong correlation in
activity (Figure 2A), as expected from the sequence alignment
of the enzymes (Figure S1), with an identity of 98%. Due to
the varied availability of the LdNMT and LmNMT enzymes,
enzymatic activity data for ligands against both LdNMT and
LmNMT enzymes was considered during the SAR analysis.
Cocrystal structures were generated solely with LmNMT
thanks to the capacity to solve structures rapidly by soaking
ligands into crystals of this protein. The SAR findings are
summarized schematically in Figure 2B.
In our previous structural analysis,30 it was proposed that
conformational variations between human and Leishmania
NMTs in LmNMT Tyr217 might be responsible for selectivity
differences.9 To assess the impact of the π interaction, we
initially investigated the importance of the inhibitor core by
exchanging the thienopyrimidine (1, 2) with a quinazoline (3,
4), a pyridopyrimidine (5), a purine (6), or a monocyclic
pyrimidine (7) (Table 1). Thienopyrimidines (1, 2), quinazo-
lines (3, 4), and pyridopyrimidine (5) exhibit comparable
potency and selectivity profiles in this series, supported by an
overlay of the crystal structures of compounds 1 and 3 in
complex with LmNMT (Figure 3A), which reveals an identical
binding mode for both compounds. In contrast, inhibitory
potency is entirely lost in the case of purine (6) and
pyrimidine (7) derivatives, which may be due to reduced
lipophilicity compared with those of 2 and 4. We therefore
focused our subsequent SAR study on C2, C4, and C6/C7
Figure 2. (A) Correlation of LmNMT-based and LdNMT-based
pIC50 values obtained with the CPM assay. The Pearson coefficient
(ρ) and P-value are shown. (B) Schematic representation of the SAR
results. The four structural segments of the inhibitor are highlighted.
All symbols are annotated in the lowest box.
Scheme 1. General Scheme for the Synthesis of 1 and Related Analoguesa
aReagents and conditions: (i) amine (1.0 equiv), N,N-diisopropylethylamine (DIPEA, 1.2 equiv), EtOAc, room temperature (rt), 18 h; (ii) amine
(4−10 equiv), EtOAc, microwave, 120−200 °C, 30−90 min; (iii) 1-chloroethyl chloroformate (1.0 equiv), DCE, reflux, 1 h; (iv) MeOH, reflux, 1
h; and (v) aldehyde (1.0 equiv), NaBH(OAc)3, DCE, rt 3−18 h.
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substituents on thienopyrimidine and quinazoline cores to
obtain small-molecule inhibitors with enhanced potency.
Effect of C2 Substitution on LdNMT and LmNMT
Enzyme Activities. We first looked at the effect of variation
in the C2 unit (Table 2). Exchanging the piperidine for a
tetrahydropyran (8) or hydroxypropyl substituent (9) resulted
in complete loss of activity. Considering the striking
differences in basicity and hydrogen-bond interaction
energies,38 these findings support the importance of the
basic center, consistent with the binding mode of compound 1
Table 1. Effect of Changing Core Structures on Enzyme- and Cell-Based Activitiesb
aSelectivity = IC50 (HsNMT1)/IC50 (LdNMT). LipE = pIC50 − clog P; where values for LdNMT and LmNMT were obtained, the average LipE is
reported. EC50 for intracellular L. donovani amastigotes.
bToxicity against bone-marrow-derived macrophages; nAUC, normalized area under the
curve. The dose−response curves are shown in Figures S6−S10.
Figure 3. Comparison of the modes of binding of selected inhibitors with varied cores or C2 substitution. MyrCoA is not shown in the binding
site, for clarity. Stereo renderings can be found in Figure S3. (A) 1 and 3 emphasizing the highly similar binding modes of the proximal ligand
pair, which differ only in the core substitution of the thienopyrimidine for a quinazoline. Protein carbons: light green or green; ligand carbons:
gray, dark gray; and waters: crimson or red. PDB ID 4cgo, 6qda. (B) 1, 10, and 12 exploring N-substitutions on the piperidine ring. As before, the
proximal ligands are closely superimposable. The same is true of the distal ligands, with the exception of the piperidine ring, which is significantly
displaced in the ethyl-substituted 12. Protein carbons: light green, green, lawn green; ligand carbons: gray, dark gray, light gray; and waters:
crimson, red, violet red. PDB ID 4cgo, 6qdb, 6qdc. (C) 1 and 2 probing the significance of linear versus cyclic amine extensions from C2 of the
core. The proximal ligand’s binding mode is altered in 2, with tilting of the thienopyrimidine core, dual conformations of the C2 amine extension,
and repositioning of the C4 aminopropionitrile. No distal ligand was observed in the LmNMT complex with 2. Protein carbons: light green or
green; ligand carbons: gray, dark gray; and waters: crimson or red. PDB ID 4cgo, 6qd9. (D) Chemical structures.
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Table 2. Effect of Changing C2 Substitution Using Thienopyrimidine and Quinazoline Cores (Compounds 8−30)
a,b
a95% CI = 95% confidence interval. Selectivity = IC50 (HsNMT)/IC50 (LdNMT). LipE = pIC50 − clog P; where values for LdNMT and LmNMT
were obtained, the average LipE is reported. EC50 for intracellular L. donovani amastigotes.
bToxicity against bone-marrow-derived macrophages;
nAUC, normalized area under the curve. The dose−response curves are shown in Figures S6−S10.
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
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and trends in previously reported ligand series.11,25,30 The
potency deviation between a tertiary (1−4) or secondary
amine as the basic center (10−11, 23) is negligible,
presumably due to calculated pK differences of less than
one unit (compound 2 pKb = 4.6; compound 11 pKb = 3.8).
However, further extending the N-methyl substituent or
inserting an aromatic system (12−16, 20) gradually decreases
the inhibitory potency, presumably because the steric demand
of the moiety is limited by the size of the pocket formed by
LmNMT Tyr80, Tyr92, Asn167, Thr203, and Leu421, and
myristoyl-CoA (MyrCoA). While the crystal structures of 1,
10, and 12 in complex with LmNMT (Figure 3B) show that
these compounds are well accommodated and show similar
binding modes, the basic centers in the C2 substituents of the
distal ligands deviate from 10 to 1 by 0.8 Å and from 1 to 12
by 1.5 Å due to steric interactions with Asp396. However,
these small differences are likely unimportant since the
proximal ligand appears to drive inhibition. Between the
overlaid proximal ligands, there is even greater similarity; for
example, the basic centers deviate by only 0.2 Å. Enhancing
the flexibility of the basic center by applying acyclic amine-
based C2 substituents (2, 4) has no effect on the inhibitory
activity against LdNMT. Considering sequence alignment
(Figure S1), the same result was expected for LmNMT;
however, 2 and 4 exhibited a 10-fold decreased activity against
the L. major enzyme. The corresponding crystal structure of 2
with LmNMT shows a small displacement of the core and
dual conformations of the C2 derivatives in the linear amine
side chain compared with 1, while no electron density was
observed for the distal ligand, suggesting it is absent (Figure
3C). There is also a significant difference observed in the
position of the aminopropionitrile group: instead of occupying
a groove composed of LmNMT Val81 and Gly205 as in 1, the
moiety is vertically aligned in compound 2. It is possible
therefore that the orientation of the C2 substituent in 2 and 4
varies between the two Leishmania enzymes.
Significantly changing the geometry of the C2 substituent
and thereby decreasing the distance between the basic center
and the core resulted in decisively reduced inhibitory potency
and selectivity (Figure 2B). This occurs if piperazine- (17−
18), pyrrolidine-amine- (19, 25−26, 53−55), or inverted
piperidine-amine (20−22)-based moieties are substituted on
either thienopyrimidine or quinazoline cores, suggesting that
the basic center and the bicyclic core must adopt a specific
conformation to permit optimal interactions in the peptide-
binding pocket of LmNMT. The crystal structure of
compound 52, which is discussed further below, supports
this rationalization (Figure 4D). The geometry of the basic
center and bicyclic core seems to be optimal in compound 1.
Further increasing degrees of freedom (2, 4) appears to be
counterproductive and results in a decreased activity in
LmNMT as discussed above. Increasing the rigidity and
bulkiness of the piperidine ring using a bicyclic system (27)
diminishes the inhibitory activity against both Ld and
LmNMT.
Finally, we explored whether variation at the first amine in
the C2 substituent was tolerated. Extending the alkyl chain
with a hydroxyethyl (28) or hydroxypropyl (29−30) group
decreases inhibitory potency, presumably due to the increased
steric demand.
Effect of C4 Substitution on LdNMT and LmNMT
Enzyme Activities. Substitution at C4 was shown to be
crucial as compound 31, a derivative of 2 lacking the
aminopropionitrile in position C4, was no longer active. We
explored the effect of differing substituents at this position
using linear moieties of similar size that, like the amino-
propionitrile, were also potential hydrogen-bond acceptors.
The results indicate that alkyl ethers (32−33), amino alcohols
(34−35, 39), and amino amides (36−38) are not tolerated
but increasing the rigidity of the alkyl ethers with a pyrrolidine
motif (40−42) restores the inhibitory activity. However,
applying the same strategy to the aminopropionitriles (43−
45) failed to improve their potency.
Figure 4. Comparison of the modes of binding of selected inhibitors with varied C4 or C6 substitution. For clarity, MyrCoA is not shown in the
binding site. Stereo renderings can be found in Figure S4. (A) 1 and 43 demonstrate similar binding interactions despite the rigidification of the
aminopropionitrile. The distal ligand does not appear, and 43 demonstrates dual conformations of the C2 substituent. Protein carbons: light
green, green; ligand carbons: gray, dark gray; and waters: crimson, red, violet red. PDB ID 4cgo, 6qdd. (B) Chemical structures of relevant
ligands. (C, D) tert-Butyl C6 substitution is accommodated in the proximal ligands for 51 and 52. However, the distal ligand conformation is
inverted in 51 and dual C2 conformations are observed in 52, which is present at partial occupancy PDB ID 4cgo, 6qde, 6qdf. (E) 2 and 56 have
analogous binding modes with an additional hydrogen bond in 56 mediated by the bromine substituent. PDB ID 4cgo, 6qdg.
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It had been noted that the aminopropionitrile side chains
had different geometries in the proximal and distal ligands
(Figure S5). Therefore, only one enantiomer was made for
compounds 40−45, in which the geometry was proposed to
match the pro-stereochemistry observed in the proximal
ligand in previous structures such as Figure 3A. Theoretically,
the proximal ligands should still be able to bind, but the C4
side chain would clash in the distal ligand and be unable to
bind (Table 3).
This was supported by the crystal structures of 1 and 43 in
complex with LmNMT, which indicated a similar binding
mode for both proximal ligands, with little deviation between
the cores and C4 substituents, and no distal ligand present.
However, the structure of 43 does show two possible
conformations of the C2 substituent (Figure 4A). This result
also helps confirm that the proximal ligand is of primary
importance for activity.
To test the impact of the nitrile group, analogues with a
simple amino ethyl moiety at C4 were synthesized (46−49).
Interestingly, this simple group is sufficient to deliver small-
molecule inhibitors with moderate activity, although at the
cost of a slight drop in selectivity over HsNMT1 (46
compared with 1 or 43). This finding supports the hypothesis
that the main role of the substituent in position C4 is to
facilitate ideal positioning of the major interaction sitesthe
Table 3. Effect of Changing C4 and C2 Substitutions on Enzyme- and Cell-Based Activities (Compounds 31−49)
a
a95% CI = 95% confidence interval. Selectivity = IC50 (HsNMT)/IC50 (LdNMT). LipE = pIC50 − clog P; where values for LdNMT and LmNMT
were obtained, the average LipE is reported. nAUC, normalized area under the curve. The dose−response curves are shown in Figures S6−S10.
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aromatic core and the basic center in the C2 moietymainly
via hydrophobic interactions.
Effect of Substitution at C6 on LdNMT and LmNMT
Enzyme Activities. Finally, we probed the effect of
substitution at C6 in combination with a range of C2
substituents. Modifications here are generally tolerated and
do not prevent binding to Leishmania NMTs. Introducing a
bulky tert-butyl group (50−54) results in a 10-fold increased
inhibitory potency (50) and a similar selectivity profile when
compared with derivatives without a C6 substituent.
Compound 50 is the most potent inhibitor in this SAR
study, with a 7-fold improved IC50 value against LdNMT of
46 nM (95% CI: 35−60 nM) and a similar selectivity
(IC50(HsNMT1)/IC50(LdNMT) = 12-fold) to that of
compound 1. The crystal structures of 51 and 52 in complex
with LmNMT reveal that the tert-butyl group has only a
modest impact on the binding mode of the proximal ligand
(Figure 4C,D). However, the distal ligand exhibits a flipped
orientation in 51, most likely due to the steric demand of the
C6 moiety that alters the conformation of LmNMT His219
(Figure 4C). In the structure with 52, there is only partial
ligand occupancy; moreover, the pyrrolidine moiety at the C2
position in the proximal ligand displays two alternate
conformations. As a result, key interactions of the basic
center with the Leu421 carboxylate and the water molecule
bound to LmNMT Tyr80, Tyr92, and Asn167 are weakened
and make a smaller contribution to binding (Figure 4D).
Considering the potency difference between 51 and 52, this
observation corroborates our hypothesis that decreased
activities of 18−22, 25−26, and 52−54 are caused by
conformational deviations in the C2 moiety.
Substitution at C6/C7 on the quinazoline core was also
explored. Inhibitors with bromo (55−57), methoxy (58−59),
or aromatic substituents (60−62) in position C6 exhibit
comparable activity and selectivity in comparison to
compounds lacking a C6 moiety. The crystal structure of
compound 56 in complex with LmNMT indicates similar
binding modes of the bromo (56) and the corresponding
thienopyrimidine derivative (2). An additional interaction is
potentially formed between the bromide and a water molecule
bound to His219 and the backbone amide of Asp396 (Figure
4E). In contrast to substitution at C6, moving the methoxy
group from C6 (59) to C7 (63) significantly decreases the
inhibitory potency.
Although the SAR discussed so far (compounds 1−63)
revealed some derivatives with significantly improved nano-
molar potency with respect to initial compound 1 (e.g., 43
and 50), none of them exhibit lipophilic efficiency (LipE;
LipE = pIC50 − clog P) values above 4 (Figure 5A). Previous
work on inhibitors for NMT in Trypanosoma brucei39 and P.
vivax8 established that interactions around PvNMT Ser319
(LmNMT Ser330) are important for higher affinity com-
pounds. In this thienopyrimidine series, the proximal ligand
does not extend into this pocket, which is occupied by the
distal ligand. To try and grow into this pocket, and to further
improve the molecules’ drug-like properties, a fragment
merging approach with DDD8564611,39 a T. brucei NMT
inhibitor was trialed. Crystallography performed on
DDD85646 in LmNMT had shown that the sulfonamide
group projected the pyrazole into the desired pocket, forming
a hydrogen bond to LmNMT Ser330 (Table 4).11
Figure 5. (A) Plot of pIC50 against clog P. Diagonal lines represent areas of corresponding lipophilic efficiency (LipE) values. (B) Plot of LipE
against selectivity (selectivity = IC50 (HsNMT)/IC50 (LdNMT)). (C) Schematic representation of fragment merging strategy between 3 and
DDD8564611 to generate 64 and related analogues. (D) Crystal structure of 1 and 64 in complex with LmNMT. 64 principally occupies the site
of the proximal ligand in 1 extending through the sulfonamide group, which forms hydrogen bonds with the LmNMT backbone amide. PDB ID
4cgo, 6qdh.
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Merged ligands were therefore proposed, in which a
sulfonamide and pyrazole group would grow off the C6
position (Figure 5C), The strongly acidic reaction conditions
required for chlorosulfonylation of the quinazoline core were
not compatible with the aminopropionitrile side chain; hence,
this modification was attempted on the more accessible N-
ethyl derivative, given that analogues 46−49 still retained
some activity. These efforts resulted in the pyrazole-based
sulfonamide derivatives 64−67.
These compounds have lower clog P values and combine
the major interactions of the distal and the proximal ligands.
The crystal structure of 64 in complex with LmNMT (Figure
5D) demonstrates the success of this approach. The
quinazoline core and C2 substituent of 64 exhibit the same
conformation in the peptide-binding pocket as the proximal
Table 4. Effect of Changing C2 and C6/7 Substitutions and Fragment Merging on Enzyme- and Cell-Based Activities
(Compounds 50−67)
a95% CI = 95% confidence interval. Selectivity = IC50 (HsNMT)/IC50 (LdNMT). LipE = pIC50 − log P; where values for LdNMT and LmNMT
were obtained, the average LipE is reported. nAUC, normalized area under the curve. The dose−response curves are shown in Figures S6−S10.
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ligand of 1, while the pyrazole moiety of 64 coincides with the
aromatic system of the distal ligand of 1. Additionally, the
sulfonamide group of 64 mediates a hydrogen bond with the
backbone amides of Gly395 and Asn396. Analysis of the
potency of all sulfonamide derivatives (64−67) revealed
decisively improved IC50 values in comparison to the
corresponding thienopyrimidine derivatives, resulting in LipE
values above 5 (Figure 5A).
However, a significant drawback of this new subseries is
their lower selectivity in relation to HsNMT1. For instance,
inhibitors 65 and 66, respectively, exhibit a decreased and
marginal selectivity of only 5.2- and 4.6-folds (Figure 5B). It is
proposed that exchanging the amino ethyl C4 substituent with
aminopropionitrile could result in sulfonamides with improved
selectivity over HsNMT1 and better early lead-compound
properties. However, these molecules have proven syntheti-
cally challenging, and the corresponding derivatives will be
part of future studies.
■ CELL-BASED ASSAYS
A selection of 22 compounds was further studied in an Alamar
blue-based cellular assay, which had been previously validated
Figure 6. (A) Plot of anti-L. donovani amastigote activity (pEC50) against macrophage toxicity (normalized area under the curve, nAUC).
Thienopyrimidine 1 is highlighted in blue. (B) Plot of Leishmania NMT pIC50 (either Ld or Lm) against cell-based pEC50. A significant
correlation (ρ = 0.75, P = 0.0006) is evident if 26, 52, and 53 (highlighted in red) are excluded. Compound 1 is highlighted in blue. (C−E) In-
gel fluorescence and anti-LdNMT Western blot results for the cell-based tagging assay. (F) Fluorescence intensities of several individual bands
between 25 and 15 kDa were quantified in (C−E) and normalized to the corresponding intensities of the control samples (without inhibitor) and
the anti-LdNMT blot results. Tagging IC50 values (TC50) were extracted by nonlinear regression with a sigmoidal dose−response model
(constraints: bottom = 0; top = 1.0) to the mean normalized intensity.
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against known anti-leishmanial drugs amphotericin B and
miltefosine,32 to quantify their cytotoxicity against macro-
phages and their activity against intracellular amastigotes of L.
donovani. Due to the steep slope of the toxicity profile and the
correspondingly low accuracy of the CC50 values, the
normalized area under the curve (nAUC) was used as the
toxicity parameter (Figure 6A). Strikingly, all compounds with
an EC50 below 50 μM that show a toxic effect against
macrophages (nAUC ≪ 1) share the tert-butyl group as C6
substituent (50−53). This increased effect on macrophages
may be due to the larger clog P and clogD values of
compounds 50−53, potentially improving membrane perme-
ability or increasing compound promiscuity. Comparing pIC50
values against Leishmania NMT with intracellular amastigote
pEC50 values indicates a good correlation for all compounds
apart from 26, 52, and 53 (Figure 6B), which show greater
potency in cells than anticipated. Interestingly, these three
inhibitors are the only derivatives tested that share a
pyrrolidine-based C2 moiety (Figure 4D).
Furthermore, 26 and 52 exhibit a 3- to 6-fold improved
EC50 value with respect to compound 1 (Figure 6A,B). To
test the hypothesis that this improved potency is due to an
on-target effect, a cell-based tagging assay22 was performed
with 1, 26, and 52 (Figure 6C−F). Briefly, L. donovani
amastigotes were treated with varying concentrations of the
corresponding compound and YnMyr, an alkyne analogue of
myristic acid.40 Following cell lysis, labeling with a trifunc-
tional capture reagent41 via copper-catalyzed azide−alkyne
cycloaddition facilitated the visualization of myristoylated
proteins by in-gel fluorescence. Western blot analysis using an
antibody against LdNMT revealed no variations of the total
protein amount or the NMT expression level over the
investigated inhibitor concentration range (Figure 6C−E),
and all three compounds (1, 26, and 52) significantly
decreased myristoylation in a dose-dependent manner. To
obtain the tagging IC50 value (TC50), a quantitative measure
of target engagement, the fluorescence intensities of several
individual bands between 25 and 15 kDa were quantified and
normalized to the corresponding intensities of the control
sample (no inhibitor) and the anti-LdNMT blot results
(loading control). The TC50 and EC50 values of compound 1
are in good agreement, indicating that the anti-L. donovani
activity is due to on-target NMT inhibition (Figure 6F).
However, the TC50 values of compounds 26 and 52 are both
5- to 6-fold above the EC50 values obtained with the Alamar
blue assay (Figure 6B). Although compounds 26 and 52 do
not show toxic off-target effects against macrophages, these
findings suggest that nonspecific effects may also contribute to
the anti-L. donovani activity for these compounds.
■ CONCLUSIONS
NMT inhibitors with a fused pyrimidine core exhibit three
sites involved in interactions with the enzyme: the aromatic
system of the core, an amine-based C4 moiety, and the basic
center in the C2 substituent. The central scaffold forms
stacking interactions with Tyr217, with scaffold lipophilicity
particularly being important. The reason for C4 preference is
less evident; although it does not appear to form any
important interactions with the protein, its contribution to
affinity may be through the quality of its packing with the C2
substituent. In the case of the C2 substituent, our data show
that a specific geometry is essential for the appropriate
positioning of the basic center. Although linear C2 moieties
are well tolerated, exchanging the piperidine with a pyrrolidine
system results in decreased activity against NMT due to a
flipped orientation in the binding pocket, leading to a different
set of hydrogen bonds. Remarkably, the corresponding
derivatives exhibit a significantly improved anti-Leishmanial
activity. In fact, compounds 26 and 52 are the most potent
derivatives in the cellular assay that additionally show no toxic
effect against macrophages. However, results from the tagging
assay suggest that although 26 and 52 cause a dose-dependent
decrease in protein-myristoylation, off-target effects may also
contribute to anti-leishmanial activity. This explanation is
supported by the fact that the pyrrolidine-based derivatives
(26, 52, and 53) are the only inhibitors that deviate from the
correlation between enzyme- and cell-based potencies. A
particularly promising new inhibitor, IMP-105 (43), exhibits
enhanced selectivity for Leishmania NMT over human NMT1
of >660-fold, while both enzyme- and cell-based activities are
maintained (Figure 7). Considering the importance of
selectivity, IMP-105 (43) is a useful tool molecule to
investigate the impact of NMT inhibition in Leishmania.
However, as yet, these compounds do not have the optimal
potency or pharmacokinetic properties to enable in vivo
experiments to be undertaken to confirm whether these
compounds can reduce parasite burden in vivo. Future studies
to further improve the potency and properties of these
compounds will focus on the combination of the improved
selectivity features shown in compound 43 with the improved
inhibitory activities and LipE values of the pyrazole-based
sulfonamides displayed by compounds 64−67.
■ EXPERIMENTAL SECTION
Chemistry General Methods. With the exception of those
described in the following sections, all chemicals were purchased
from Sigma-Aldrich Ltd. (Gillingham, U.K.), Apollo Scientific
(Stockport, U.K.), Acros Organics (Geel, Belgium), Alfa Aesar
(Heysham, U.K.), or TCI-UK (Oxford, U.K.) and were used without
further purification.
Microwave-assisted experiments were undertaken on a Biotage
Initiator using Biotage microwave vials (2−5 mL), which were sealed
and heated to the targeted temperature using variable power to
maintain the set temperature.
Flash column chromatography of compounds was undertaken
either using an Isolera One (Biotage) or manually on silica gel
(silicagel 60 [40−63 μm]) using glass columns and an appropriate
solvent mixture.
High-performance liquid chromatography (HPLC) of compounds
was undertaken using a Gilson semipreparative reverse-phase HPLC
system equipped with a HICHROM C18 Column (250 mm × 21.2
mm), #306 pumps, and a Gilson UV/vis detector, detecting at 220
nm. For the latter, the mobile phase consisted of water + 0.1% formic
acid (solvent A) and methanol + 0.1% formic acid (solvent B), with
an elution method of 0−2 min 5% B, 2−30 min 5−98% B, 30−32
min 98% B, and 32−32.5 min 2% B at a flow rate of 12 mL/min.
Figure 7. Comparison between ligands 1 and 43.
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For liquid chromatography-mass spectrometry (LC-MS), the
compounds were purified and analyzed on an LC-MS system
equipped with both an XBridge prep C18 5 μm, 19 mm × 100 mm
OBD column, and an XBridge C18 5 μm, 4.6 mm × 100 mm
column. Unless specified otherwise, all compounds were analyzed
over a gradient of methanol in water (5−98% over 12 min and then
98% methanol for 3 min at a flow rate of 1.2 mL/min), both
containing 0.1% formic acid. Alternative gradient elutions started
from 20 or 50% methanol for the same time periods. Retention times
(Rt) and mass peaks (MH
+) were recorded, and purity was
determined as >95% by integration of the diode array trace, unless
otherwise stated.
1H and 13C NMR spectra were recorded at 400 and 101 MHz,
respectively, on Bruker AV instruments at room temperature and
referenced to residual solvent signals. Data are presented as follows:
chemical shift in ppm, multiplicity (br = broad, app = apparent, s =
singlet, d = doublet, t = triplet, q = quartet, p = pentet, m =
multiplet), coupling constants in Hz, and integration.
High-resolution mass spectra were obtained from the Mass
Spectrometry Service of the Department of Chemistry, Imperial
College London.
General Synthetic Methods. General Method for C4 Displace-
ments (Method A). To a solution of the appropriate 2,4-dichloro-
fused pyrimidine intermediate (1.0 equiv) in EtOAc (10 mL) was
added DIPEA (1.2 equiv) followed by the appropriate amine (1.0
equiv), and the reaction was stirred at room temperature overnight.
The reaction mixture was washed with sodium hydroxide solution (1
M, 10 mL), and the aqueous layer was re-extracted with EtOAc (10
mL). The combined organic layers were dried (Na2SO4) and then
concentrated under reduced pressure. Where necessary, the crude
product was purified by flash column chromatography.
General Method for Displacement at C2 (Method B). The
appropriate 4-amino-2-chloro-fused pyrimidine (1.0 equiv) was
suspended in EtOAc (1 mL) in a 2 mL Biotage microwave vial.
An excess of the appropriate amine (4−10 equiv) was added, and the
vial was sealed. The closed vial was heated in a Biotage Initiator
microwave oven for 30−90 min to a fixed target temperature of
between 120 and 180 °C depending on the molecule. The reaction
mixture was partitioned between EtOAc (20 mL) and sodium
hydroxide solution (1 M, 10 mL), and then the aqueous layer was re-
extracted with EtOAc (10 mL). The combined organic layers were
dried (Na2SO4) and concentrated under reduced pressure. The crude
product was purified by flash column chromatography or by reverse-
phase HPLC. Fractions containing the desired product were
combined and evaporated under reduced pressure or partially
evaporated and lyophilized after HPLC purification.
General Method for Debenzylation (Method C). A solution of
the appropriate N-benzyl derivative in 1,2-dichloroethane (DCE, 5.0
mL) was cooled to 0 °C before the addition of 1-chloroethyl
chloroformate (ACE-Cl, 1.0 equiv). The reaction mixture was heated
under reflux for 1 h, cooled to room temperature, and then
evaporated to dryness. The intermediate was redissolved in methanol
(5.0 mL) and returned to reflux for a further 1 h. The reaction
mixture was evaporated once again and partitioned between EtOAc
(10 mL) and sodium hydroxide solution (1 M, 10 mL), and then the
aqueous layer was re-extracted with EtOAc (10 mL). The combined
organic layers were dried (Na2SO4) and concentrated under reduced
pressure. The crude product was purified by flash column
chromatography or by reverse-phase HPLC. Fractions containing
the desired product were combined and evaporated under reduced
pressure or partially evaporated and lyophilized after HPLC
purification.
General Method for Reductive Amination (Method D). A
solution of the appropriate amine in DCE was treated with a solution
of the appropriate aldehyde (1−10 equiv) in DCE. The solution was
stirred at room temperature for 15 min before being treated with
solid sodium triacetoxyborohydride (4−10 mol equiv). The mixture
was stirred for 3−18 h at room temperature until complete by thin-
layer chromatography (TLC) and then partitioned between CH2Cl2
(20 mL) and saturated NaHCO3 solution (10 mL). The organic
phase was dried over Na2SO4, concentrated under reduced pressure,
and the crude product was purified by reverse-phase HPLC.
Fractions containing the desired product were partially evaporated
and lyophilized after HPLC purification.
Synthesis of Final Compounds. 3-(Methyl(2-(methyl(1-meth-
ylpiperidin-4-yl)amino)thieno[3,2-d]pyrimidin-4-yl)amino)-
propanenitrile (1). According to general method D for reductive
amination, 3-(methyl(2-(methyl(piperidin-4-yl)amino)thieno[3,2-d]-
pyrimidin-4-yl)amino)propanenitrile (11, 0.033 g, 0.1 mmol) was
dissolved in DCE (3 mL) and treated with paraformaldehyde (6.0
mg, 0.2 mmol). After stirring at room temperature for 10 min, solid
sodium triacetoxyborohydride (85 mg, 0.4 mmol) was added, and
the resulting suspension was stirred at room temperature overnight.
After workup, the crude product was purified by reverse-phase HPLC
(50−98% MeOH/water/0.1% formic acid), partially evaporated, and
then lyophilized to give the title compound (1) as a formate salt
(24.9 mg, 0.064 mmol, 64%). LC-MS Rt = 5.9 min; MH
+ 345; 1H
NMR (400 MHz, CD3OD) δ 8.38 (s, 2H), 7.94 (d, J = 5.5 Hz, 1H),
7.20 (d, J = 5.5 Hz, 1H), 4.99−4.95 (m, 1H), 4.08 (t, J = 6.6 Hz,
2H), 3.64−3.59 (m, 2H), 3.56 (s, 3H), 3.20 (dt, J = 12.8, 3.0 Hz,
2H), 3.07 (s, 3H), 2.93 (t, J = 6.6 Hz, 2H), 2.88 (s, 3H), 2.19 (dq, J
= 12.9, 3.6 Hz, 2H), 2.01−1.95 (m, 2H). ESI HRMS, found
345.1875 (C17H25N6S, [M + H]
+, requires 345.1861).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (2). According to
general method B for C2 displacements, intermediate IM1 (50.0
mg, 0.20 mmol) was suspended in EtOAc (1 mL) in a microwave
vial and treated with excess N,N,N′-trimethyl-1,3-propane-diamine
(0.5 mL, 2 mmol). After workup, the crude product was purified by
reverse-phase HPLC (20−98% MeOH/water/0.1% formic acid) to
give the title compound (2) as the formate salt (12 mg, 0.032 mmol,
16%). LC-MS Rt = 3.8 min; MH
+ 333; 1H NMR (400 MHz, CDCl3)
δ 8.55 (s, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.14 (d, J = 5.5 Hz, 1H),
4.00 (t, J = 7.0 Hz, 2H), 3.70 (t, J = 7.0 Hz, 2H), 3.55 (s, 3H), 3.15
(s, 3H), 2.81 (t, J = 7.0 Hz, 2H), 2.65 (t, J = 7.0 Hz, 2H), 2.48 (s,
6H), 2.03−1.88 (m, 2H); 13C NMR (101 MHz, CDCl3), δ 186.3,
167.8, 163.9, 160.3, 157.9, 132.1, 124.2, 118.6, 56.6, 47.7, 47.3, 44.4,
38.5, 35.6, 24.8, 16.3; ESI HRMS, found 333.1861 (C16H25N6S [M +
H]+, requires 333.1869).
3-(Methyl(2-(methyl(1-methylpiperidin-4-yl)amino)quinazolin-
4-yl)amino)propanenitrile (3). 3-(Methyl(2-(methyl(piperidin-4-yl)-
amino)quinazolin-4-yl)amino)propanenitrile (23, 0.022 g, 0.068
mmol) was dissolved in DCE (1 mL) and treated with
paraformaldehyde (15.0 mg, 0.5 mmol). After stirring at room
temperature for 10 min, solid sodium triacetoxyborohydride (44 mg,
0.21 mmol) was added, and the resulting suspension was stirred at
room temperature overnight. After workup, the crude product was
purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
formic acid), partially evaporated, and then lyophilized to give the
title compound (3) as a di-formate salt (2.9 mg, 0.007 mmol, 10%).
LC-MS Rt = 5.98 min; MH
+ 339; 1H NMR (400 MHz, CD3OD) δ
8.39 (s, 3H), 8.20 (dd, J = 8.4, 1.0 Hz, 1H), 7.78−7.74 (m, 1H),
7.69 (dd, J = 8.4, 1.1 Hz, 1H), 7.39 (dt, J = 8.3, 1.2 Hz, 1H), 5.06−
4.98 (m, 1H), 4.19 (t, J = 6.8 Hz, 2H), 3.65 (s, 3H), 3.65−3.58 (m,
2H), 3.24−3.18 (m, 4H), 3.18 (s, 3H), 3.03 (t, J = 6.8 Hz, 2H), 2.85
(s, 3H), 2.31−2.19 (m, 2H), 2.05−2.00 (m, 2H). ESI HRMS, found
339.2299 (C19H27N6 [M + H]
+ requires 339.2297).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)quinazolin-4-
yl)(methyl)amino)propanenitrile (4). According to general method
B for C2 displacements, intermediate IM2 (0.04 g, 0.16 mmol) was
suspended in EtOAc (1 mL) in a microwave vial and treated with
excess N,N,N′-trimethyl-1,3-propane-diamine (200 μL, 1.6 mmol).
The vial was sealed and irradiated for 30 min at 150 °C. After
workup, the crude product was purified by reverse-phase HPLC
(30−98% MeOH/water/0.1% formic acid), partially evaporated, and
then lyophilized to give the title compound, 4, as a colorless di-
formate salt (9.2 mg, 0.022 mmol, 14%). LC-MS Rt = 6.8 min; MH
+
327; 1H NMR (400 MHz, CD3OD) δ 8.52 (s, 2H), 8.14 (dd, J = 8.5,
1.4 Hz, 1H), 7.72 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.60 (d, J = 8.5 Hz,
1H), 7.31 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 4.15 (t, J = 6.7 Hz, 2H),
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3.84 (t, J = 7.0 Hz, 2H), 3.61 (s, 3H), 3.30 (s, 3H), 3.16 (t, J = 7.0
Hz, 2H), 3.05 (t, J = 6.7 Hz, 2H), 2.88 (s, 6H), 2.18 (p, J = 7.0 Hz,
2H); ESI HRMS, found 327.2302 (C18H27N6 [M + H]
+, requires
327.2297).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)pyrido[2,3-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (5). According to
general method B for C2 displacements, intermediate IM3 (0.022
g, 0.09 mmol) was suspended in EtOAc (1 mL) in a 2 mL
microwave vial and treated with excess N,N,N′-trimethyl-1,3-
propane-diamine (50 μL, 0.40 mmol). The vial was sealed and
irradiated for 30 min at 150 °C. After workup, the crude product was
purified by reverse-phase HPLC (20−98% MeOH/water/0.1%
formic acid), partially evaporated and then lyophilized to give the
title compound, 5, as a pale yellow formate salt (21.1 mg, 0.056
mmol, 64%). LC-MS Rt = 1.7 min; MH
+ 328; 1H NMR (400 MHz,
CD3OD) δ 8.67 (dd, J = 4.5, 1.7 Hz, 1H), 8.53 (dd, J = 8.4, 1.7 Hz,
1H), 8.45 (s, 1H), 7.18 (dd, J = 8.4, 4.5 Hz, 1H), 4.11 (t, J = 6.7 Hz,
2H), 3.79 (m, 2H), 3.58 (s, 3H), 3.26 (s, 3H), 3.13−3.07 (m, 2H),
3.01 (t, J = 6.7 Hz, 2H), 2.88 (s, 6H), 2.19−2.11 (m, 2H); ESI
HRMS, found 328.2263 (C17H26N7 [M + H]
+ requires 328.225).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-7-methyl-7H-
purin-6-yl)(methyl)amino)propanenitrile (6). According to general
method B for C2 displacements, intermediate IM4 (0.021g, 0.08
mmol) was suspended in EtOAc (1 mL) in a 2 mL microwave vial
and treated with excess N,N,N′-trimethyl-1,3-propane-diamine (200
μL, 0.8 mmol). The vial was sealed and irradiated for 30 min at 150
°C. After workup, the crude residue was purified by reverse-phase
HPLC (50−98% MeOH/water/0.1% formic acid) to give the title
compound as a colorless formate salt (13 mg, 0.035 mmol, 44%).
LC-MS Rt = 1.6 min; MH
+ 331; 1H NMR (400 MHz, CD3OD) δ
8.55 (s, 1H), 8.04 (s, 1H), 4.00 (s, 3H), 3.84 (t, J = 6.6 Hz, 2H),
3.69 (t, J = 6.6 Hz, 2H), 3.25 (s, 3H), 3.17 (s, 3H), 2.92 (t, J = 6.6
Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.67 (s, 6H), 2.02 (p, J = 6.6 Hz,
2H). ESI HRMS, found 331.2365 (C16H27N8 [M + H]
+, requires
331.2359).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)pyrimidin-4-yl)-
(methyl)amino)propanenitrile (7). 3-((2-Chloropyrimidin-4-yl)-
(methyl)amino)propanenitrile (IM22, 50 mg, 0.25 mmol) and
N,N,N′-trimethyl-1,3-propane-diamine (149 μL, 1.02 mmol) were
dissolved in n-BuOH (1.0 mL) and heated at 120 °C for 4 h. After
cooling, the solution was diluted with EtOAc, washed with H2O and
then brine, dried over MgSO4, and concentrated in vacuo. The
residue was purified by reverse-phase HPLC (50−98% MeOH/
water/0.1% formic acid) to give the title compound 7 (67 mg, 0.20
mmol, 82%). LC-MS Rt = 1.04 min; MH
+ 277.4; 1H NMR (400
MHz, CDCl3) δ 8.47 (s, 1H), 7.95 (d, J = 5.9 Hz, 1H), 5.81 (d, J =
6.0 Hz, 1H), 3.86 (t, J = 6.6 Hz, 2H), 3.66 (t, J = 6.9 Hz, 2H), 3.09
(s, 6H), 2.93−2.85 (m, 2H), 2.71 (t, J = 6.5 Hz, 2H), 2.65 (s, 6H),
2.07−1.99 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 167.8, 161.7,
161.1, 156.4, 92.4, 55.4, 46.5, 45.8, 42.8, 36.6, 35.2, 23.2, 16.2; ESI
HRMS, found 277.2142 (C14H25N6 [M + H]
+, requires 277.2141).
3-(Methyl(2-(methyl(tetrahydro-2H-pyran-4-yl)amino)thieno-
[3,2-d]pyrimidin-4-yl)amino)propanenitrile (8). According to gen-
eral method B for C2 displacements, intermediate IM1 (0.025 g, 0.1
mmol) was suspended in EtOAc (1 mL) in a 2 mL Biotage
microwave vial and treated with excess N-methyltetrahydro-2H-
pyran-4-amine (92 mg, 0.8 mmol). After workup, the crude product
was purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
formic acid) to give the title compound (8), as a formate salt (5.0
mg, 0.013 mmol, 13%). 1H NMR (400 MHz, CD3OD) δ 8.31 (s,
2H), 7.98 (d, J = 5.6 Hz, 1H), 7.22 (d, J = 5.6 Hz, 1H), 4.13−4.04
(m, 6H), 3.59 (s, 3H), 3.07 (s, 3H), 2.94−2.91 (m, 1H), 2.92 (t, J =
6.7 Hz, 2H), 1.98−1.60 (m, 4H), ESI HRMS, found 332.1549
(C16H22N5OS [M + H]
+, requires 332.1545).
3-((2-((3-Hydroxypropyl)(methyl)amino)thieno[3,2-d]pyrimidin-
4-yl)(methyl)amino)propanenitrile (9). According to general meth-
od B for C2 displacements, intermediate IM1 (0.025 g, 0.1 mmol)
was suspended in EtOAc (1 mL) in a microwave vial and treated
with excess 3-(methylamino)propan-1-ol (80 mg, 0.8 mmol). The
vial was sealed and irradiated for 30 min at 120 °C. After workup, the
crude residue was purified by reverse-phase HPLC (50−98%
MeOH/water/0.1% formic acid) to give the title compound (9) as
a formate salt (5.0 mg, 0.014 mmol, 14%). LC-MS Rt = 9.3 min;
MH+ 306; 1H NMR (400 MHz, CD3OD) δ 8.58 (s, 1H), 7.83 (d, J
= 5.5 Hz, 1H), 7.12 (d, J = 5.5 Hz, 1H), 4.05 (t, J = 6.5 Hz, 2H),
3.74 (t, J = 6.5 Hz, 2H), 3.61 (t, J = 6.5 Hz, 2H), 3.54 (s, 3H), 3.17
(s, 3H), 3.15−3.04 (m, 1H), 2.90 (t, J = 6.5 Hz, 2H), 1.94−1.78 (m,
2H); 13C NMR (101 MHz, CD3OD) δ 162.7, 161.9, 160.1, 157.9,
132.5, 122.5, 118.4, 59.1, 58.7, 46.0, 37.1, 34.6, 30.2 15.1; ESI
HRMS, found 306.1402 (C14H20N5OS [M + H]
+, requires
306.1389).
3-(Methyl(2-(methyl(piperidin-4-yl)amino)thieno[3,2-d]-
pyrimidin-4-yl)amino)propanenitrile (10). According to general
method C for debenzylation, a solution of 3-((2-((1-benzylpiper-
idin-4-yl)(methyl)amino)thieno[3,2-d]pyrimidin-4-yl)(methyl)-
amino)propanenitrile (14, 380 mg, 0.9 mmol) in DCE (7 mL) was
reacted with 1-chloroethyl chloroformate (107 μL, 0.9 mmol). After
workup, the crude product was purified by flash column
chromatography (CH2Cl2/MeOH/aq. NH3; 95:5:0.5−90:10:1−
80:20:1) to give the title compound (10) as an orange foam (150
mg, 0.45 mmol, 50%). LC-MS Rt = 6.0 min; MH
+ 331; 1H NMR
(400 MHz, CDCl3) δ 7.56 (d, J = 5.4 Hz, 1H), 7.11 (d, J = 5.4 Hz,
1H), 4.70 (m, 1H), 3.94 (t, J = 6.8 Hz, 2H), 3.49 (s, 3H), 3.20 (m,
2H), 3.05 (br, 1H), 3.01 (s, 3H), 2.80−2.73 (m, 4H), 1.80−1.68 (m,
4H); ESI HRMS, found 331.1718 (C16H23N6S [M + H]
+, requires
331.1705).
3-(Methyl-(2-(methyl-(3-(methylamino)propyl)amino)thieno-
[3,2-d]pyrimidin-4-yl)amino)propanenitrile (11). According to
general method B for C2 displacements, intermediate IM1 (0.025
g, 0.1 mmol) was suspended in EtOAc (1 mL) in a microwave vial
and treated with excess N,N′-dimethylpropane-1,3-diamine (80 mg,
0.8 mmol). The vial was sealed and irradiated for 30 min at 120 °C.
After workup, the crude residue was purified by reverse-phase HPLC
(30−98% MeOH/water/0.1% formic acid) to give the title
compound (11) as a formate salt (1.6 mg, 0.044 mmol, 4%). LC-
MS Rt = 6.1 min; MH
+ 319; 1H NMR (400 MHz, CD3OD) δ 8.44
(s, 2H), 7.91 (d, J = 5.5 Hz, 1H), 7.20 (d, J = 5.5 Hz, 1H), 4.09 (t, J
= 6.5 Hz, 2H), 3.74 (t, J = 6.5 Hz, 2H), 3.57 (s, 3H), 3.18 (s, 3H),
2.97 (t, J = 6.5 Hz, 2H), 2.91 (t, J = 6.5 Hz, 2H), 2.64 (s, 3H),
2.10−1.98 (m, 2H); ESI HRMS, found 319.1714 (C15H23N6S [M +
H]+, requires 319.1705).
3-(Methyl(2-(methyl(1-ethylpiperidin-4-yl)amino)thieno[3,2-d]-
pyrimidin-4-yl)amino)propanenitrile (12). According to general
method D for reductive amination, 3-(methyl(2-(methyl(piperidin-
4-yl)amino)thieno[3,2-d]pyrimidin-4-yl)amino)propanenitrile (10,
0.030 g, 0.1 mmol) was dissolved in DCE (3 mL), treated with
acetaldehyde (10 mL, 0.2 mmol) and solid sodium triacetoxybor-
ohydride (85 mg, 0.4 mmol), and then stirred at room temperature
overnight. After workup, the crude residue was purified by reverse-
phase HPLC (50−98% MeOH/water/0.1% formic acid), partially
evaporated, and then lyophilized. The product was impure and so
was repurified by reverse-phase HPLC (20−98% MeOH/water/0.1%
formic acid) to give the title compound (12) as a di-formate salt
(13.8 mg, 0.031 mmol, 31%). LC-MS Rt = 6.6 min; MH
+ 359; 1H
NMR (400 MHz, CD3OD) δ 8.43 (s, 2H), 7.89 (d, J = 5.5 Hz, 1H),
7.17 (d, J = 5.5 Hz, 1H), 5.01−4.93 (m, 1H), 4.08 (t, J = 7.0 Hz,
2H), 3.71−3.65 (m, 2H), 3.55 (s, 3H), 3.20 (q, J = 7.0 Hz, 2H),
3.14 (dt, J = 13.1, 2.6 Hz, 2H), 3.07 (s, 3H), 2.90 (t, J = 7.0 Hz,
2H), 2.21−2.10 (m, 2H), 2.04−1.97 (m, 2H), 1.37 (t, J = 7.0 Hz,
3H); ESI HRMS, found 359.2001 (C18H27N6S [M + H]
+, requires
359.2018).
3-((2-((1-Isobutylpiperidin-4-yl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (13). According to
general method D for reductive amination, 3-(methyl(2-(methyl-
(piperidin-4-yl)amino)thieno[3,2-d]pyrimidin-4-yl)amino)-
propanenitrile (10, 0.030 g, 0.1 mmol) was dissolved in DCE (3 mL)
and treated with isobutyraldehyde (7.2 mg, 0.1 mmol) and then
sodium triacetoxyborohydride (85 mg, 0.4 mmol) before stirring at
room temperature overnight. After workup, the crude product was
purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
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formic acid), partially evaporated, and then lyophilized to give the
title compound (13) as a formate salt (22.0 mg, 0.051 mmol, 51%).
LC-MS Rt = 7.8 min; MH
+ 387; 1H NMR (CD3OD, δ, ppm) 8.41 (s,
2H), 7.91 (d, J = 5.5 Hz, 1H), 7.18 (d, J = 5.5 Hz, 1H), 4.96 (m,
1H), 4.08 (t, J = 7.0 Hz, 2H), 3.72−3.66 (m, 2H), 3.56 (s, 3H), 3.15
(dt, J = 13.0, 2.9 Hz, 2H), 3.07 (s, 3H), 2.98 (d, J = 7.0 Hz, 2H),
2.90 (t, J = 7.0 Hz, 2H), 2.29−2.13 (m, 3H), 2.00−1.95 (m, 2H),
1.10 (d, J = 7.0 Hz, 6H); ESI HRMS, found 387.2323 (C20H31N6S,
[M + H]+, requires 387.2331).
3-((2-((1-Benzylpiperidin-4-yl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (14). According to
general method B for C2 displacements, intermediate IM1 (0.25 g,
1.0 mmol) was suspended in EtOAc (3 mL) in a microwave vial and
treated with excess 1-benzyl-N-methylpiperidin-4-amine (830 mg, 4
mmol). The vial was sealed and irradiated for 90 min at 180 °C.
After workup, the crude product was purified by column
chromatography on silica by elution with CH2Cl2 and then
CH2Cl2/MeOH/aq. NH3 solution (97:3:0.5). A second column
(EtOAc, 100%) gave the title compound (14) as a colorless oil (380
mg, 0.090 mmol, 90%). LC-MS Rt = 8.8 min; MH
+ 421; 1H NMR
(400 MHz, CDCl3) δ 7.59 (d, J = 5.5 Hz, 1H), 7.37−7.27 (m, 5H),
7.14 (d, J = 5.5 Hz, 1H), 4.62 (t, J = 11.5 Hz, 1H), 3.98 (t, J = 6.8
Hz, 2H), 3.55 (m, 5H), 3.03 (m, 5H), 2.79 (t, J = 6.8 Hz, 2H),
2.20−2.10 (m, 2H), 1.94−1.84 (m, 2H), 1.671 (d, J = 11.5 Hz, 2H);
ESI HRMS, found 421.2187 (C23H29N6S [M + H]
+, requires
421.2174).
3-((2-((3-(Isobutyl(methyl)amino)propyl)(methyl)-amino)thieno-
[3,2-d]pyrimidin-4-yl)(methyl)-amino)propanenitrile (15). Accord-
ing to general method D, 3-(methyl(2-(methyl(3-(methylamino)-
propyl)amino)thieno[3,2-d]pyrimidin-4-yl)amino)propanenitrile (11,
0.032 g, 0.1 mmol) was dissolved in DCE (3 mL) and treated with
isobutyraldehyde (7.2 mg, 0.1 mmol). After stirring at room
temperature for 10 min, solid sodium triacetoxyborohydride (85
mg, 0.4 mmol) was added, and the resulting suspension was stirred at
room temperature overnight. After workup, the crude product was
purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
formic acid), partially evaporated, and then lyophilized to give the
title compound 15 as a formate salt (5.0 mg; 0.012 mol, 12%). LC-
MS Rt = 7.9 min; MH
+ 375; 1H NMR (400 MHz, CDCl3) δ 8.51 (s,
1H), 7.61 (d, J = 5.4 Hz, 1H), 7.13 (d, J = 5.4 Hz, 1H), 3.99 (t, J =
6.6 Hz, 2H), 3.68 (t, J = 6.6 Hz, 2H), 3.54 (s, 3H), 3.14 (s, 3H),
2.82−2.75 (m, 4H), 2.52−2.47 (m, 5H), 2.00−1.99 (m, 3H), 0.97
(d, J = 6.6 Hz, 6H); ESI HRMS, found 375.2345 (C19H31N6S [M +
H]+, requires 375.2331).
3-((2-((3-(Benzyl(methyl)amino)propyl)(methyl)amino)thieno-
[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (16). Accord-
ing to general method D, 3-(methyl(2-(methyl(3-(methylamino)-
propyl)amino)thieno[3,2-d]pyrimidin-4-yl)amino)propanenitrile (11,
0.032 g, 0.1 mmol) was dissolved in DCE (3 mL) and treated with
benzaldehyde (10 mg, 0.1 mmol) and then sodium triacetoxybor-
ohydride (85 mg, 0.4 mmol). The resulting suspension was stirred at
room temperature overnight, and after workup, the crude product
was purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
formic acid), partially evaporated, and then lyophilized to give the
title compound (16) as a formate salt (7.0 mg, 0.015 mmol, 15%).
LC-MS Rt = 8.4 min; MH
+ 409; 1H NMR (400 MHz, CDCl3) δ 8.53
(s, 1H), 8.46 (s, 1H), 7.62 (d, J = 5.5 Hz, 1H), 7.36−7.31 (m, 5H),
7.09 (d, J = 5.5 Hz, 1H), 4.00 (s, 2H), 3.96 (t, J = 6.6 Hz, 2H), 3.68
(t, J = 6.6 Hz, 2H), 3.55 (s, 3H), 3.11 (s, 3H), 2.90−2.85 (m, 2H),
2.76 (t, J = 6.6 Hz, 2H), 2.53 (s, 3H), 2.11−2.02 (m, 2H); ESI
HRMS found 409.2165, (C22H29N6S [M + H]
+, requires 409.2174).
3-(Methyl(2-(piperazin-1-yl)thieno[3,2-d]pyrimidin-4-yl)amino)-
propanenitrile (17). According to general method B for C2
displacements, intermediate IM1 (0.025 g, 0.1 mmol) was suspended
in EtOAc (1 mL) in a microwave vial and treated with excess
piperazine (70 mg, 0.8 mmol). The vial was sealed and irradiated for
30 min at 120 °C. After workup, the crude product was purified by
reverse-phase HPLC (50−98% MeOH/water/0.1% formic acid) to
give the title compound (17) as a formate salt (1.5 mg, 0.004 mmol,
4%). LC-MS Rt = 8.1 min; MH
+ 303; 1H NMR (400 MHz, CD3OD)
δ 8.42 (s, 1H), 7.91 (d, J = 5.5 Hz, 1H), 7.15 (d, J = 5.5 Hz, 1H),
4.08 (t, J = 6.5 Hz, 2H), 4.06−4.02 (m, 4H), 3.79−3.70 (m, 2H),
3.57 (s, 3H), 3.29−3.25 (m, 4H), 2.88 (t, J = 6.5 Hz, 2H); ESI
HRMS, found 303.1394 (C14H19N6S [M + H]
+, requires 303.1392).
3-(Methyl(2-(4-methylpiperazin-1-yl)thieno[3,2-d]pyrimidin-4-
yl)amino)propanenitrile (18). According to general method B for C2
displacements, intermediate IM1 (0.05 g, 0.2 mmol) was suspended
in ethyl acetate (1 mL) in a microwave vial and treated with excess
N-methylpiperazine (0.3 mL, 2 mmol). The vial was sealed and
irradiated for 30 min at 120 °C. After workup, the crude product was
purified by flash column chromatography using CH2Cl2 and then
CH2Cl2/MeOH/aq. NH3 solution (95:5:0.5) to give the title
compound (18) as a colorless solid (45 mg, 0.14 mmol, 72%).
LC-MS Rt = 5.2 min; MH
+ 317; 1H NMR (400 MHz, CDCl3) δ 7.65
(d, J = 5.7 Hz, 1H), 7.18 (d, J = 5.7 Hz, 1H), 4.01 (t, J = 6.6 Hz,
2H), 3.84 (dd, J = 6.1, 4.1 Hz, 4H), 3.57 (s, 3H), 2.81 (t, J = 6.6 Hz,
2H), 2.60−2.47 (m, 4H), 2.37 (s, 3H); ESI HRMS, found 317.1542
(C15H21N6S [M + H]
+, requires 317.1548).
3-((2-((1-Benzylpyrrolidin-3-yl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (19). According to
general method B for C2 displacements, intermediate IM1 (0.10 g,
0.4 mmol) was suspended in EtOAc (1.5 mL) in a microwave vial
and treated with excess 1-benzyl-N-methylpyrrolidin-3-amine (385
μL, 2.0 mmol). The vial was sealed and irradiated for 90 min at 180
°C. After workup, the crude product was purified by flash column
chromatography using EtOAc (100%) and then CH2Cl2/MeOH/aq.
NH3 (97:3:0.5) to give the title compound (19) as a colorless oil (95
mg, 0.23 mmol, 58%). LC-MS Rt = 8.5 min; MH
+ 407; 1H NMR
(400 MHz, CDCl3) δ 7.61 (d, J = 5.4 Hz, 1H), 7.43−7.25 (m, 5H),
7.17 (d, J = 5.4 Hz, 1H), 5.57−5.50 (m, 1H), 3.99 (t, J = 6.6 Hz,
2H), 3.73 (d, J = 12.8 Hz, 1H), 3.61 (d, J = 12.8 Hz, 1H), 3.56 (s,
3H,), 3.15 (s, 3H), 2.93−2.87 (m,1H), 2.79 (t, J = 6.6 Hz, 2H),
2.74−2.65 (m, 2H), 2.54−2.46 (m, 1H), 2.28−2.19 (m, 1H), 1.95−
1.86 (m, 1H); ESI HRMS, found 407.2010 (C22H27N6S [M + H]
+,
requires 407.2018).
3-((2-(4-(Ethylamino)piperidin-1-yl)thieno[3,2-d]pyrimidin-4-yl)-
(methyl)amino)propanenitrile (20). According to general method B
for C2 displacements, intermediate IM1 (0.025 g, 0.1 mmol) was
suspended in EtOAc (1.5 mL) in a microwave vial and treated with
excess N-ethyl-1-methylpiperidin-4-amine (0.4 mmol). The vial was
sealed and irradiated for 90 min at 180 °C. After workup, the crude
product was purified by reverse-phase HPLC (50−98% MeOH/
water) to give the title compound (20) as a di-formate salt (3.5 mg,
0.008 mmol, 8%). 1H NMR (400 MHz, CDCl3) δ 8.38 (br s, 2H),
7.89 (d, J = 5.5 Hz, 1H), 7.14 (d, J = 5.5 Hz), 4.88−4.84 (m, 2H),
4.07 (t, J = 6.7 Hz, 2H), 3.56 (s, 3H), 3.43−3.35 (m, 1H), 3.42−
3.35 (m, 1H), 3.15−3.10 (q, J = 7.3 Hz, 2H), 3.02−2.94 (m, 2H),
2.88 (t, J = 6.4 Hz), 2.18−2.10 (m, 2H), 1.62−1.53 (m, 2H), 1.32 (t,
J = 7.3 Hz, 3H). ESI HRMS, found 345.1886 (C17H25N6S [M + H]
+,
requires 345.1861).
3-((2-((3S,4S)-3-Fluoro-4-(methylamino)piperidin-1-yl)thieno-
[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (21). Accord-
ing to general method B for C2 displacements, intermediate IM1
(0.025 g, 0.1 mmol) was suspended in EtOAc (1.5 mL) in a
microwave vial and treated with excess (3S,4S)-3-fluoro-N,1-
dimethylpiperidin-4-amine (0.088 g, 0.4 mmol). The vial was sealed
and irradiated for 90 min at 180 °C. After workup, the crude product
was purified by reverse-phase HPLC (20−98% MeOH/water) to
give the title compound (21) as a formate salt (7.0 mg, 0.018 mmol,
18%). 1H NMR (400 MHz, MeOD) δ 8.55 (br s, 1H), 7.91 (d, J =
5.5 Hz, 1H), 7.18 (d, J = 5.6 Hz, 1H), 5.08 (dtd, J = 12.4, 5.1, 2.0
Hz, 1H), 4.79 (ddd, J = 13.7, 4.7, 2.4 Hz, 1H), 4.59 (dtd, J = 50.0,
9.8, 5.3 Hz, 1H), 4.09 (t, J = 6.6 Hz, 2H), 3.58 (s, 3H), 3.11−2.95
(m, 2H), 2.91 (t, J = 6.6 Hz, 3H), 2.70 (s, 3H), 2.23 (ddt, J = 12.9,
5.0, 2.5 Hz, 1H), 1.58 (qd, J = 12.4, 4.5 Hz, 1H); ESI HRMS, found
349.1623 (C16H22N6SF [M + H]
+, requires 349.1611).
3-((2-((3R,4S)-3-Fluoro-4-(methylamino)piperidin-1-yl)thieno-
[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (22). Accord-
ing to general method B for C2 displacements, intermediate IM1
(0.025 g, 0.1 mmol) was suspended in EtOAc (1.5 mL) in a
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microwave vial and treated with excess (3R,4S)-3-fluoro-N,1-
dimethylpiperidin-4-amine (0.088 g, 0.4 mmol). The vial was sealed
and irradiated for 90 min at 180 °C. After workup, the crude product
was purified by reverse-phase HPLC (50−98% MeOH/water) to
give the title compound (22) as a formate salt (6.4 mg, 0.016 mmol,
16%). 1H NMR (400 MHz, MeOD) δ 8.40 (s, 1H), 7.88 (d, J = 5.5
Hz, 1H), 7.14 (d, J = 5.6 Hz, 1H), 5.26 (ddt, J = 14.9, 12.0, 2.9 Hz,
1H), 5.14 (d, J = 49.7 Hz, 1H), 4.99−4.92* (m, 1H), 4.14−4.00 (m,
2H), 3.59−3.46 (m, 4H), 3.28−3.12 (m, 1H), 3.04−2.96 (m, 1H),
2.89 (td, J = 6.7, 1.8 Hz, 2H), 2.11−2.05 (m, 1H), 1.98−1.87 (m,
1H); ESI HRMS, found 349.1594 (C16H22N6SF [M + H]
+, requires
349.1611). *Partially obscured by the H2O signal.
3-(Methyl(2-(methyl(piperidin-4-yl)amino)quinazolin-4-yl)-
amino)propanenitrile (23). 3-((2-Chloroquinazolin-4-yl)(methyl)-
amino)propanenitrile (IM2) (50 mg, 0.20 mmol, 1.0 equiv) was
dissolved in n-BuOH (1.0 mL), and 1-benzyl-N-methylpiperidin-4-
amine (163 mg, 0.80 mmol, 4.0 equiv) was added. The reaction was
heated at 200 °C for 2 h. After cooling to room temperature, the
reaction mixture was partitioned between EtOAc (20 mL) and
sodium hydroxide solution (1 M, 10 mL), and then the aqueous
layer was re-extracted with EtOAc (10 mL). The combined organic
layers were dried (Na2SO4) and concentrated under reduced
pressure. The crude product was purified by flash column
chromatography with CH2Cl2/MeOH (10:1) to give 3-((2-((1-
benzylpyrrolidin-3-yl)(methyl)amino)quinazolin-4-yl)(methyl)-
amino)propanenitrile (88 mg). This intermediate was then
debenzylated using 10% Pd/C (22 mg) and ammonium formate
(126 mg) in EtOH (2.0 mL). After filtration through celite and
concentration in vacuo, the residue was purified by reverse-phase
HPLC (20−98% MeOH/water/0.1% formic acid), partially evapo-
rated, and then lyophilized to give the title compound (23) as a
formate salt (33 mg, 0.089 mmol, 44% over two steps). LC-MS Rt =
8.8 min. 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 2H), 8.17 (dd, J =
8.4, 1.2 Hz, 1H), 7.78−7.61 (m, 2H), 7.35 (ddd, J = 8.4, 6.8, 1.5
Hz), 5.02*, 4.17 (t, J = 7.1 Hz, 2H), 3.57 (m, 1H), 3.55 (m, 1H),
3.26−3.18 (m, 2H), 3.18 (s, 3H), 2.16 (m, 2H), 2.04 (m, 1H), 2.01
(m, 1H). ESI HRMS, found 325.2166 (C18H25N6 [M + H]
+, requires
325.2141). *Partially obscured by the H2O signal and identified by
analogy with compound 3.
3-((2-((1-Ethylpiperidin-4-yl)(methyl)amino)quinazolin-4-yl)-
(methyl)amino)propanenitrile (24). In a variation on general
method D for reductive amination, 3-(methyl(2-(methyl(piperidin-
4-yl)amino)quinazolin-4-yl)amino)propanenitrile (23, 0.009 g, 0.028
mmol) was dissolved in DCM (1 mL) and treated with
isobutyraldehyde (5.0 μL, 0.14 mmol). After stirring at room
temperature for 10 min, solid sodium triacetoxyborohydride (30 mg,
0.14 mmol) was added, and the resulting suspension was stirred at
room temperature overnight. After workup, the crude product was
purified by reverse-phase HPLC (5−98% MeOH/water/0.1% formic
acid), partially evaporated, and then lyophilized to give the title
compound (24) as a 2.5 × formate salt (2.0 mg, 0.004 mmol, 15%).
1H NMR (400 MHz, CDCl3) δ 8.35 (br s, 2H), 8.14 (d, J = 8.4 Hz,
1H), 7.71 (ddd, J = 8.3, 7.0, 1.0 Hz, 1H), 7.63 (dd, J = 8.4, 0.9 Hz,
1H), 7.31 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 5.50 (tt, J = 12.1, 4.0 Hz,
1H), 4.14 (t, J = 6.9 Hz, 2H), 3.67 (m, 2H), 3.60 (s, 3H), 3.21−3.10
(m, 7H), 3.02 (t, J = 6.9 Hz, 2H), 2.19 (m, 2H), 2.04 (m, 2H), 1.37
(t, J = 7.2 Hz, 3H); ESI HRMS, found 353.2449 (C20H29N6 [M +
H]+, requires 353.2454).
3-(Methyl(2-(methyl(pyrrolidin-3-yl)amino)quinazolin-4-yl)-
amino)propanenitrile (25). 3-((2-Chloroquinazolin-4-yl)(methyl)-
amino)propanenitrile (IM2) (50 mg, 0.20 mmol, 1.0 equiv) was
dissolved in n-BuOH (1.0 mL), and 1-benzyl-N-methylpyrrolidin-3-
amine (154 μL, 0.80 mmol, 4.0 equiv) was added. The reaction was
heated at 120 °C for 2 h. After cooling to room temperature, the
reaction mixture was partitioned between EtOAc (20 mL) and
sodium hydroxide solution (1 M, 10 mL), and then the aqueous
layer was re-extracted with EtOAc (10 mL). The combined organic
layers were dried (Na2SO4) and concentrated under reduced
pressure. The crude product was purified by flash column
chromatography with CH2Cl2/MeOH (10:1) to give 3-((2-((1-
benzylpyrrolidin-3-yl)(methyl)amino)quinazolin-4-yl)(methyl)-
amino)propanenitrile (41 mg, 0.10 mmol). This intermediate (24
mg, 0.06 mmol) was then debenzylated using 10% Pd/C (7 mg) and
ammonium formate (38 mg, 0.6 mmol) in EtOH (2.0 mL). After
filtration through celite and concentration in vacuo, the residue was
purified by reverse-phase HPLC (5−98% MeOH/water/0.1% formic
acid), partially evaporated, and then lyophilized to give the title
compound (25) as a formate salt (1.5 mg, 0.004 mmol, 67%). LC-
MS Rt = 9.6 min.
1H NMR (400 MHz, CDCl3) δ 8.48 (s br, 1H),
8.04 (dd, J = 8.4, 0.9 Hz, 1H), 7.61 (m, 1H), 7.53 (dd, J = 8.4, 1.0
Hz, 1H), 7.19 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 5.22 (m, 1H), 4.03 (t,
J = 6.7 Hz, 2H), 3.71 (ddd, J = 11.8, 8.6, 3.3 Hz, 1H), 3.52−3.42 (m,
5H), 3.31−3.26 (m, 1H), 3.25 (s, 3H), 2.99 (t, J = 6.6 Hz, 2H),
2.45−2.34 (m, 1H), 2.31−2.20 (m, 1H); ESI HRMS, found
311.1985 (C17H23N6 [M + H]
+, requires 311.1984).
3-(Methyl(2-(methyl(1-methylpyrrolidin-3-yl)amino)quinazolin-
4-yl)amino)propanenitrile (26). In a variation on general method D
for reductive amination, 3-(methyl(2-(methyl(pyrrolidin-3-yl)-
amino)quinazolin-4-yl)amino)propanenitrile (25, 3.1 mg, 0.01
mmol, 1.0 equiv) was dissolved in DCM (1 mL) and treated with
formaldehyde (10 equiv). After stirring at room temperature for 10
min, solid sodium triacetoxyborohydride (11 mg, 0.05 mmol, 5.0
equiv) was added, and the resulting suspension was stirred at room
temperature overnight. After workup, the crude product was purified
by reverse-phase HPLC (5−98% MeOH/water/0.1% formic acid),
partially evaporated, and then lyophilized to give the title compound
(26) as a yellow oil (2.4 mg, 0.007 mmol, 74%). LC-MS Rt = 2.7
min; MH+ 325; 1H NMR (400 MHz, CDCl3) δ 7.96 (dd, J = 8.5, 1.1
Hz, 1H), 7.53 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.46 (dd, J = 8.5, 1.1
Hz, 1H), 7.10 (ddd, J = 8.3, 6.6, 1.2 Hz, 1H), 5.68−5.60 (m, 1H),
3.46 (s, 3H), 3.14 (s, 3H), 2.97 (t, J = 6.8 Hz, 2H), 2.85−2.77 (m,
2H), 2.70−2.61 (m, 2H), 2.42 (s, 3H), 2.28−2.18 (m, 1H), 2.00−
1.91 (m, 1H); ESI HRMS, found 325.2132 (C18H25N6 [M + H]
+,
requires 325.2141).
3-(Methyl(2-(methyl((1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]-
octan-3-yl)amino)quinazolin-4-yl)amino)propanenitrile (27). Ac-
cording to general method B for C2 displacements, intermediate IM2
(0.03 g, 0.12 mmol) was suspended in EtOAc (1 mL) in a
microwave vial and treated with excess (1R,3R,5S)-N,8-dimethyl-8-
azabicyclo[3.2.1]octan-3-amine (0.115 g, 0.75 mmol). The vial was
sealed and irradiated for 90 min at 150 °C. After workup, the crude
residue was purified by reverse-phase HPLC (30−98% MeOH/
water/0.1% formic acid), partially evaporated, and then lyophilized.
The product was repurified using gradient elution (10−98% MeOH/
water/0.1% formic acid), partially evaporated, and then lyophilized to
give the title compound (27) as a colorless di-formate salt (2.9 mg,
0.006 mmol, 5%). LC-MS Rt = 7.1 min; MH
+ 365; 1H NMR (400
MHz, CD3OD) δ 8.47 (s, 2H), 8.08 (dd, J = 8.5, 1.4 Hz, 1H), 7.65
(ddd, J = 8.5, 6.8, 1.4 Hz, 1H), 7.57 (dd, J = 8.5, 1.4 Hz, 1H), 7.24
(ddd, J = 8.5, 6.8, 1.4 Hz, 1H), 5.44 (m, 1H), 4.12 (t, J = 7.0 Hz,
2H), 4.07−4.00 (m, 2H), 3.56 (s, 3H), 3.14 (s, 3H), 3.04 (t, J = 7.0
Hz, 2H), 2.87 (s, 3H), 2.48 (m, 2H), 2.39−2.22 (m, 4H), 1.98 (m,
2H). ESI HRMS, found 365.246 (C21H29N6 [M + H]
+, requires
365.2454).
3-((2-((2-Hydroxyethyl)(piperidin-4-yl)amino)quinazolin-4-yl)-
(methyl)amino)propanenitrile (28). According to general method B
for C2 displacements, intermediate IM2 (50 mg, 0.20 mmol) was
suspended in n-BuOH (1 mL) in a microwave vial and treated with
excess 2-((1-benzylpiperidin-4-yl)amino)ethanol (188 mg, 0.80
mmol). The vial was sealed and irradiated at 200 °C for 2 h. After
workup, the crude residue was purified by flash column
chromatography (CH2Cl2/MeOH; 95:5) to give the intermediate
3-((2-((1-benzylpiperidin-4-yl)(2-hydroxyethyl)amino)quinazolin-4-
yl)(methyl)amino)propanenitrile (32 mg, 0.072 mmol, 36%). The
intermediate was debenzylated with 10% Pd/C (10 mg) and
ammonium formate (50 mg, 0.79 mmol) in EtOH (2.0 mL). After
filtration through celite, the filtrate was concentrated in vacuo and
then purified by reverse-phase HPLC (5−98% MeOH/water/0.1%
formic acid) to give the title compound, 28, as a di-formate salt (2.0
mg, 0.004 mmol, 5%). LC-MS Rt = 6.2 min; MH
+ 355; 1H NMR
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(400 MHz, CD3OD) δ 8.39 (s, 2H), 8.08 (dd, J = 8.3, 1.0 Hz, 1H),
7.64 (ddd, J = 8.5, 7.2, 1.3 Hz, 1H), 7.48 (dd, J = 8.3, 0.8 Hz, 1H),
7.24 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 5.02−4.96* (m, 1H), 4.10 (t, J
= 7.0 Hz, 2H), 3.82 (d, J = 5.6 Hz, 2H), 3.71 (d, J = 5.6 Hz, 2H),
3.59−3.52 (m, 5H), 3.25−3.18 (m, 2H), 3.00 (t, J = 7.0 Hz, 2H),
2.10−2.04 (m, 4H); ESI HRMS, found 355.2242 (C19H27N6O [M +
H]+, requires 355.2246). *Partially obscured by the H2O signal.
3-((2-((3-Hydroxypropyl)(piperidin-4-yl)amino)quinazolin-4-yl)-
(methyl)amino)propanenitrile (29). In a variation on general
method B for C2 displacements, intermediate IM2 (50 mg, 0.20
mmol) was suspended in n-BuOH (1 mL) in a microwave vial and
treated with excess 3-((1-benzylpiperidin-4-yl)amino)propan-1-ol
(198 mg, 0.80 mmol). The vial was sealed and irradiated at 200
°C for 2 h. After workup, the crude residue was purified by flash
column chromatography (CH2Cl2/MeOH; 95/5) to give the
intermediate 3-((2-((1-benzylpiperidin-4-yl)(3-hydroxypropyl)-
amino)quinazolin-4-yl)(methyl)amino)propanenitrile (45 mg, 0.098
mmol, 49%). The intermediate was debenzylated with 10% Pd/C
(11 mg) and ammonium formate (63 mg, 1.0 mmol) in EtOH (2.0
mL). After filtration through celite, the filtrate was concentrated in
vacuo and then purified by reverse-phase HPLC (5−98% MeOH/
water/0.1% formic acid) to give the title compound, 29, as a di-
formate salt (12.0 mg, 0.026 mmol, 13%). LC-MS Rt = 7.0 min;
MH+ 369; 1H NMR (400 MHz, CD3OD) δ 8.41 (s, 2H), 8.14 (dd, J
= 8.4, 1.0 Hz, 1H), 7.69 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.51 (d, J =
8.2 Hz, 1H), 7.30 (ddd, J = 8.2, 7.2, 1.1 Hz, 1H), 4.99−4.92* (m,
1H), 4.14 (t, J = 7.0 Hz, 2H), 3.73−3.69 (m, 4H), 3.60 (s, 3H),
3.60−3.53 (m, 2H), 3.25−3.17 (m, 2H), 3.00 (t, J = 6.8 Hz, 2H),
2.19−2.07 (m, 4H), 1.92 (qt, J = 6.2 Hz, 2H); ESI HRMS, found
369.2399 (C20H29N6O [M + H]
+, requires 369.2403). *Partially
obscured by the H2O signal.
3-((2-((3-Hydroxypropyl)(1-methylpiperidin-4-yl)amino)-
quinazolin-4-yl)(methyl)amino)propanenitrile (30). In a variation
of general method D for reductive amination, 3-((2-((3-
hydroxypropyl)(piperidin-4-yl)amino)quinazolin-4-yl)(methyl)-
amino)propanenitrile (29, 9.0 mg, 0.024 mmol, 1.0 equiv) was
dissolved in DCM (2.0 mL) and treated with formaldehyde (10
equiv). After stirring at room temperature for 10 min, solid sodium
triacetoxyborohydride (16 mg, 0.072 mmol, 3.0 equiv) was added,
and the resulting suspension was stirred at room temperature
overnight. After workup, the crude product was purified by reverse-
phase HPLC (5−98% MeOH/water/0.1% formic acid), partially
evaporated, and then lyophilized to give the title compound, 30, as a
formate salt (2.0 mg, 0.005 mmol, 19%). LC-MS Rt = 6.9 min; MH
+
383.5; 1H NMR (400 MHz, CD3OD) δ 8.49 (s, 1H), 8.05 (dd, J =
8.4, 1.0 Hz, 1H), 7.61 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.44 (dd, J =
8.4, 1.0 Hz, 1H), 7.20 (ddd, J = 8.4, 6.8, 1.3 Hz, 1H), 4.97−4.90*
(m, 1H), 4.07 (t, J = 7.0 Hz, 2H), 3.68 (dt, J = 11.7, 6.3 Hz, 2H),
5.54−5.49 (m, 5H), 3.07 (dt, J = 12.8, 2.8 Hz, 2H), 2.99 (t, J = 7.0
Hz, 2H), 2.80 (s, 3H), 2.21−2.20 (m, 4H), 1.88 (qt, J = 6.4 Hz,
2H); ESI HRMS, found 383.2578 (C21H31N6O [M + H]
+, requires
383.2559). *Partially obscured by the H2O signal.
N1,N1,N3-Trimethyl-N3-(thieno[3,2-d]pyrimidin-2-yl)propane-1,3-
diamine (31). 2-Chlorothieno[3,2-d]pyrimidine (10 mg, 0.059
mmol) was dissolved in N,N-dimethylacetamide (DMA, 1.0 mL),
and N,N,N′-trimethyl-1,3-propane-diamine (52 μL) was added and
then sealed and heated at 120 °C for 4 h. The reaction mixture was
partitioned between EtOAc (10 mL) and 1 M NaOH solution (5
mL), and then the aqueous layer was re-extracted with EtOAc (10
mL). The combined organic layers were dried (Na2SO4) and
concentrated under reduced pressure. The crude product was
purified by flash column chromatography to give the product (31)
as a colorless oil (9.0 mg, 0.036 mmol, 61%) with a purity of 90%.
LC-MS Rt = 8.3 min; MH
+ 251.3 1H NMR (400 MHz, CDCl3) δ
8.81 (s, 1H), 7.76 (d, J = 5.4 Hz, 1H), 7.20 (d, J = 5.4 Hz, 1H), 3.75
(t, J = 7.2 Hz, 2H), 3.23 (s, 3H), 2.35 (t, J = 7.4 Hz, 2H), 2.26 (s,
6H), 1.84 (m, 2H). ESI HRMS, found 251.1331 (C12H19N4S [M +
H]+, requires 251.1330).
N2-(3-(Dimethylamino)propyl)-N4-(2-methoxyethyl)-N2,N4-
dimethylthieno[3,2-d]pyrimidine-2,4-diamine (32). According to
general method B for C2 displacements, intermediate IM5 (50 mg,
0.19 mmol) was suspended in EtOAc (1 mL) in a microwave vial
and treated with excess N,N,N′-trimethyl-1,3-propane-diamine (0.5
mL, 2.0 mmol) and then sealed and irradiated for 30 min at 120 °C.
After workup, the crude product was purified by reverse-phase HPLC
(20−98% MeOH/water/0.1% formic acid) to give the title
compound (33) (5.3 mg, 0.016 mmol, 8%). LC-MS Rt = 7.6 min;
MH+ 338; 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 5.5 Hz, 1H),
7.14 (d, J = 5.5 Hz, 1H), 3.90 (t, J = 6.0 Hz, 2H), 3.75−3.58 (m,
4H), 3.44 (s, 3H), 3.36 (s, 3H), 3.15 (s, 3H), 2.56 (t, J = 6.0 Hz,
2H), 2.41 (s, 6H), 1.93 (m, 2H); 13C NMR (101 MHz, CDCl3) δ
163.2, 160.3, 158.3, 131.3, 124.0, 104.8, 71.3, 59.2, 57.0, 50.8, 47.4,
44.8, 38.7, 35.6, 25.1; ESI HRMS, found 338.2014 (C16H28N5OS [M
+ H]+ requires 338.2015).
N-(2-Methoxyethyl)-N-methyl-2-(4-methylpiperazin-1-yl)thieno-
[3,2-d]pyrimidin-4-amine (33). According to general method B for
C2 displacements, intermediate IM5 (50 mg, 0.19 mmol) was
suspended in EtOAc (1 mL) in a microwave vial and treated with
excess N-methylpiperazine (0.3 mL, 2.0 mmol). The vial was sealed
and irradiated for 30 min at 120 °C. After workup, the crude product
was purified by reverse-phase HPLC (20−98% MeOH/water/0.1%
formic acid) to give the title compound (33) as a formate salt (21
mg, 0.057 mmol, 30%). LC-MS Rt = 7.0 min; MH
+ 322; 1H NMR
(400 MHz, CDCl3) δ 8.49 (s, 1H), 7.57 (d, J = 5.5 Hz, 1H), 7.13 (d,
J = 5.5 Hz, 1H), 3.90 (t, J = 5.8 Hz, 2H), 3.87−3.83 (m, 4H), 3.66
(t, J = 5.8 Hz, 2H), 3.45 (s, 3H), 3.36 (s, 3H), 2.57 (m, 4H), 2.39 (s,
3H); 13C NMR (101 MHz, CDCl3) δ 167.9, 163.2, 160.2, 158.3,
131.4, 124.0, 71.1, 59.1, 54.8, 50.8, 45.8, 43.9, 38.7; ESI HRMS,
found 322.1696 (C15H24N5OS [M + H]
+ requires 322.1688).
2-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)ethanol (34). According to general
method B for C2 displacements, intermediate IM6 (50 mg, 0.21
mmol) was suspended in EtOAc (1 mL) in a microwave vial and
treated with excess N,N,N′-trimethyl-1,3-propane-diamine (0.5 mL, 2
mmol). The vial was sealed and irradiated for 30 min at 120 °C.
After workup, the crude product was purified by reverse-phase HPLC
(20−98% MeOH/water/0.1% formic acid) to give the title
compound (34) as a formate salt (22 mg, 0.06 mmol, 28%). LC-
MS Rt = 6.1 min; MH
+ 324; 1H NMR (400 MHz, CDCl3) δ 8.54 (s,
1H), 7.64 (d, J = 5.5 Hz, 1H), 7.20 (d, J = 5.5 Hz, 1H), 4.47 (s, 1H),
3.98−3.84 (m, 4H), 3.78 (t, J = 6.9 Hz, 2H), 3.52 (s, 3H), 3.18 (s,
3H), 3.06−2.95 (m, 2H), 2.70 (s, 6H), 2.17−1.99 (m, 2H); 13C
NMR (101 MHz, CDCl3) δ 168.6, 162.5, 159.8, 159.0, 32.1, 123.7,
60.0, 55.4, 53.2, 47.0, 42.8, 38.1, 35.4, 23.3; ESI HRMS, found
324.1863 (C15H26N5OS [M + H]
+ requires 324.1858).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propan-1-ol (35 ) . 2-((2-
Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)ethanol IM7 (23
mg, 0.088 mmol, 1.0 equiv) was dissolved in n-BuOH, and N,N,N′-
trimethyl-1,3-propane-diamine (78 μL, 0.53 mmol, 6.0 equiv) was
added. The reagents were heated at 150 °C under MW radiation for
1 h and then concentrated in vacuo. The residue was purified by
reverse-phase HPLC (5−98% MeOH/water/0.1% formic acid) to
give the title compound (35) as a formate salt (5.7 mg, 0.015 mmol,
17%). LC-MS Rt = 7.16 min; MH
+ 338; 1H NMR (400 MHz,
CD3OD) δ 8.57 (s, 1H), 7.89 (d, J = 5.5 Hz, 1H), 7.19 (d, J = 5.5
Hz, 1H), 3.90 (t, J = 7.3 Hz), 3.72 (t, J = 6.3 Hz, 2H), 3.67 (t, J =
6.1 Hz, 2H), 3.45 (s, 3H), 3.18 (s, 3H), 3.08 (t, J = 6.9 Hz, 2H),
2.85 (s, 6H), 2.09 (q, J = 6.6 Hz, 2H), 1.99−1.89 (m, 2H); ESI
HRMS, found 338.2013 (C16H36N5OS, [M + H]
+, requires
338.2015).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propenamide (36). 3-((2-
Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propenamide
(IM8) (24 mg, 0.088 mmol, 1.0 equiv), was dissolved in EtOAc (1.0
mL) and N,N-dimethylformamide (DMF, 1.0 mL), and then N,N,N′-
trimethyl-1,3-propane-diamine (78 μL, 0.53 mmol, 6.0 equiv) was
added. The reagents were heated at 150 °C under MW radiation for
1 hr and then concentrated in vacuo. The residue was purified by
reverse-phase HPLC (5−98% MeOH/water/0.1% formic acid) to
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give the title compound (36) as a formate salt (8.8 mg, 0.022 mmol,
25%). Purity 85%; LC-MS Rt = 5.4 min; MH
+ 351; 1H NMR
(CD3OD, δ, ppm) δ 8.07 (d, J = 5.5 Hz, 1H), 7.30 (d, J = 5.5 Hz,
1H), 4.16−4.09 (m, 2H), 3.77 (t, J = 6.8 Hz, 2H), 3.57 (s, 3H), 3.24
(s, 3H), 3.22−3.16 (m, 2H), 2.91 (s, 6H), 2.68 (s, 6H), 2.72−2.62
(m, 2H); ESI HRMS, found 351.1957 (C16H27N6OS, [M + H]
+,
requires 351.1967).
N-(2-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-
d]pyrimidin-4-yl)(methyl)amino)ethyl)-N-methylacetamide (37).
According to general method B for C2 displacements, intermediate
IM9 (20 mg, 0.07 mmol) was suspended in EtOAc in a microwave
vial and treated with excess N,N,N′-trimethyl-1,3-propane-diamine
(100 μL, 0.8 mmol). The vial was sealed and irradiated for 30 min at
150 °C. After workup, the crude product was purified by reverse-
phase HPLC (20−98% MeOH/water/0.1% formic acid) to give the
title compound (37) as a formate salt as a mixture of rotamers (7.1
mg, 0.017 mmol, 23%). LC-MS Rt = 6.9 min; MH
+ 379; 1H NMR
(400 MHz, CD3OD) δ 8.58 (s, 1H), 7.87 (d, J = 5.4 Hz, 0.3H), 7.85
(d, J = 5.4 Hz, 0.7H), 7.22−7.13 (m, 1H), 4.04 (t, J = 6.0 Hz, 0.6H),
3.99 (t, J = 6.0 Hz, 1.4H), 3.78−3.65 (m, 4H), 3.50 (d, J = 2.0 Hz,
3H), 3.19 (s, 3H), 3.10 (s, 2H), 3.01 (m, 1H), 2.63 (m, 2H), 2.49 (s,
3H), 2.46 (s, 2H), 2.04 (s, 2H), 2.02 (s, 1H), 1.95 (m, 2H); ESI
HRMS, found 379.2287 (C18H31N6OS [M + H]
+ requires 379.228).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)-N,N-dimethylpropanamide (38). 3-
((6-(tert-Butyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)-
amino)propanenitrile IM10 (42 mg, 0.14 mmol) was suspended in
DMA (1 mL) in a microwave vial, treated with excess N,N,N′-
trimethyl-1,3-propane-diamine (80 μL, 0.55 mmol), and then heated
for 24 h at 100 °C. After workup, the crude product was purified by
reverse-phase HPLC (20−98% MeOH/water/0.1% formic acid) to
give the title compound (38) as a formate salt (11.6 mg, 0.027
mmol, 19%). LC-MS Rt = 7.1 min; MH
+ 379; 1H NMR (400 MHz,
CD3OD) δ 8.58 (s, 1H), 7.85 (d, J = 5.5 Hz, 1H), 7.17 (d, J = 5.5
Hz, 1H), 4.13−4.01 (m, 2H), 3.70 (t, J = 7.0 Hz, 2H), 3.48 (s, 3H),
3.18 (s, 3H), 3.06 (s, 3H), 2.97 (s, 3H), 2.89−2.79 (m, 2H), 2.70 (t,
J = 7.0 Hz, 2H), 2.53 (s, 6H), 1.97 (p, 2H); ESI HRMS, found
379.2282 (C18H31N6OS [M + H]
+ requires 379.228).
(S)-(1-(2-((3-(Dimethylamino)propyl)(methyl)amino)thieno[3,2-
d]pyrimidin-4-yl)pyrrolidin-2-yl)methanol (39). According to gen-
eral method B for C2 displacements, intermediate IM11 (27 mg, 0.1
mmol) was suspended in EtOAc (1 mL) in a microwave vial and
treated with excess N,N,N′-trimethyl-1,3-propane-diamine (127 μL,
1.0 mmol). The vial was sealed and irradiated for 30 min at 120 °C.
After workup, the crude product was purified by reverse-phase HPLC
(30−98% MeOH/water/0.1% formic acid) to give the title
compound (39) as a formate salt (12.1 mg, 0.031 mmol, 31%).
LC-MS Rt = 7.0 min; MH
+ 350; 1H NMR (CD3OD, δ, ppm) 8.45 (s,
2H), 7.93 (d, J = 5.4 Hz, 1H), 7.20 (d, J = 5.4 Hz, 1H), 4.63−4.56
(m, 1H), 4.09−4.01 (m, 1H), 3.97−3.89 (m, 1H), 3.89−3.84 (m,
1H), 3.74−3.64 (m, 2H), 3.69−3.84 (m, 1H), 3.19 (s, 3H), 3.10 (t, J
= 7.1 Hz, 2H), 2.86 (s, 6H), 2.78−2.68 (m, 1H), 2.32−2.01 (m,
6H); ESI HRMS, found 350. 2017 (C17H28N5OS [M + H]
+ requires
350.2015).
(S)-4-(2-(Methoxymethyl)pyrrolidin-1-yl)-N-methyl-N-(1-methyl-
piperidin-4-yl)thieno[3,2-d]pyrimidin-2-amine (40). According to
general method D for reductive amination, (S)-4-(2-
(methoxymethyl)pyrrolidin-1-yl)-N-methyl-N-(piperidin-4-yl)thieno-
[3,2-d]pyrimidin-2-amine (41, 15 mg, 0.04 mmol) was dissolved in
DCE (5 mL) and treated with paraformaldehyde (6.0 mg, 0.2
mmol). After stirring at room temperature for 10 min, solid sodium
triacetoxyborohydride (85 mg, 0.4 mmol) was added, and the
resulting suspension was stirred at room temperature overnight. After
workup, the crude product was purified by reverse-phase HPLC
(30−98% MeOH/water/0.1% formic acid), partially evaporated, and
then lyophilized to give the title compound (40) as a colorless
formate salt (6.8 mg, 0.016 mmol, 40%). LC-MS Rt = 8.3 min; MH
+
376; 1H NMR (400 MHz, CD3OD) δ 8.49 (s, 2H), 7.87 (d, J = 5.4
Hz, 1H), 7.15 (d, J = 5.4 Hz, 1H), 4.87−4.84* (m, 1H), 4.68−4.61
(m, 1H), 4.05−3.99 (m, 1H), 3.91−3.84 (m, 1H), 3.73 (dd, J = 9.0,
3.1 Hz, 1H), 3.59−3.51 (m, 2H), 3.43 (t, J = 8.4 Hz, 1H), 3.38 (s,
3H), 3.12−2.99 (m, 5H), 2.84 (s, 3H), 2.26−2.01 (m, 6H), 2.00−
1.91 (m, 2H); ESI HRMS, found 376.2185 (C19H30N5OS [M + H]
+
requires 376.2171). *Partially obscured by the H2O signal.
(S)-4-(2-(Methoxymethyl)pyrrolidin-1-yl)-N-methyl-N-(piperidin-
4-yl)thieno[3,2-d]pyrimidin-2-amine (41). According to general
method B for C2 displacements, intermediate IM12 (0.10 g, 0.35
mmol) was suspended in EtOAc (1.5 mL) in a microwave vial and
treated with excess 1-benzyl-N-methylpiperidin-4-amine (430 μL, 2.1
mmol). The vial was sealed and irradiated for 90 min at 180 °C.
After workup, the crude product was purified by flash column
chromatography (EtOAc, 100%) to give the intermediate, N-(1-
benzylpiperidin-4-yl)-4-(2-(methoxymethyl)pyrrolidin-1-yl)-N-
methylthieno[3,2-d]pyrimidin-2-amine, a colorless oil (140 mg, 0.31
mmol, 89%). 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 5.4 Hz,
1H), 7.39−7.24 (m, 5H), 7.15 (d, J = 5.4 Hz, 1H), 4.71 (m, 1H),
4.67−4.62 (m, 1H), 4.00 (m, 1H), 3.84 (m, 1H), 3.77 (m, 1H), 3.56
(s, 2H), 3.38 (s, 3H), 3.35 (m, 1H), 3.08 (s, 3H), 3.02 (m, 2H),
2.25−2.08 (m, 5H), 1.89 (m, 3H), 1.71 (m, 2H).
The intermediate (140 mg, 0.31 mmol) was then debenzylated
according to general method C. After workup, the crude product was
purified by reverse-phase HPLC (50−98% MeOH/water/0.1%
formic acid), partially evaporated and then lyophilized to give the
title compound (41) as a di-formate salt (18.9 mg, 0.042 mmol,
13%). LC-MS Rt = 8.3 min; MH
+ 362; 1H NMR (400 MHz,
CD3OD) δ 8.42 (s, 1H), 7.96 (d, J = 5.5 Hz, 1H), 7.22 (d, J = 5.5
Hz, 1H), 4.91−4.87* (m, 1H), 4.69−4.64 (m, 1H), 4.05 (td, J = 9.1,
2.4 Hz, 1H), 3.90 (td, J = 9.4, 7.0 Hz, 1H), 3.73 (dd, J = 9.0, 3.1 Hz,
1H), 3.61−3.52 (m, 2H), 3.43 (dd, J = 9.0, 7.9 Hz, 1H), 3.38 (s,
3H), 3.22−3.11 (m, 2H), 3.09 (s, 3H), 2.29−2.13 (m, 1H), 2.16−
1.95 (m, 7H) *Partially obscured by the H2O signal.
(S)-N1-(4-(2-(Methoxymethyl)pyrrolidin-1-yl)thieno[3,2-d]-
pyrimidin-2-yl)-N1,N3,N3-trimethylpropane-1,3-diamine (42). Ac-
cording to general method B for C2 displacements, intermediate
IM12 (15 mg, 0.053 mmol) was suspended in EtOAc (1 mL) in a
microwave vial and treated with excess N,N,N′-trimethyl-1,3-
propane-diamine (100 μL, 0.78 mmol). The vial was sealed and
irradiated for 30 min at 150 °C. After workup, the crude product was
purified by reverse-phase HPLC (30−98% MeOH/water/0.1%
formic acid) to give the title compound (42) as a formate salt
(3.3 mg, 0.008 mmol, 15%). LC-MS Rt = 8.4 min; MH
+ 364; 1H
NMR (400 MHz, CD3OD) δ 8.55 (s, 1H), 7.83 (d, J = 5.5 Hz, 1H),
7.14 (d, J = 5.5 Hz, 1H), 4.68−4.61 (m, 1H), 4.04−3.94 (m, 1H),
3.91−3.84 (m, 1H), 3.73 (dd, J = 9.2, 3.1 Hz, 1H), 3.71−3.63 (m,
2H), 3.48 (dd, J = 9.0, 7.8 Hz, 1H), 3.37 (s, 3H), 3.16 (s, 3H), 2.72
(t, J = 7.3 Hz, 2H), 2.55 (s, 6H), 2.23−2.01 (m, 4H), 2.01−1.91 (m,
2H); ESI HRMS, found 364.2182 (C18H30N5OS [M + H]
+ requires
364.2171).
(S)-2-(1-(2-(Methyl(1-methylpiperidin-4-yl)amino)thieno[3,2-d]-
pyrimidin-4-yl)pyrrolidin-2-yl)acetonitrile (43). According to gen-
eral method D for reductive amination, (S)-2-(1-(2-(methyl-
(piperidin-4-yl)amino)thieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)-
acetonitrile (44, 15 mg, 0.042 mmol) was reacted with
paraformaldehyde (6.0 mg, 0.2 mmol) and sodium triacetoxybor-
ohydride (85 mg, 0.4 mmol). After workup, the crude product was
purified by reverse-phase HPLC (30−98% MeOH/water/0.1%
formic acid), partially evaporated, and then lyophilized to give the
title compound (43) as a formate salt (9.6 mg, 0.023 mmol, 55%).
LC-MS Rt = 7.5 min; MH
+ 371; 1H NMR (400 MHz, CD3OD) δ
8.42 (s, 2H), 7.90 (d, J = 5.5 Hz, 1H), 7.17 (d, J = 5.5 Hz, 1H),
5.03−4.93 (m, 1H), 4.78−4.72 (m, 1H), 4.15−4.09 (m, 1H), 4.00−
3.93 (m, 1H), 3.65−3.57 (m, 2H), 3.25−3.15 (m, 2H), 3.13−3.08
(m, 1H), 3.07 (s, 3H), 2.92−2.84 (m, 1H), 2.88 (s, 3H), 2.35−2.11
(m, 5H), 2.04−1.93 (m, 3H); ESI HRMS, found 371.2020
(C19H27N6S [M + H]
+ requires 371.2018).
(S)-2-(1-(2-(Methyl(piperidin-4-yl)amino)thieno[3,2-d]pyrimidin-
4-yl)pyrrolidin-2-yl)acetonitrile (44). According to general method B
for C2 displacements, intermediate IM13 (0.10 g, 0.35 mmol) was
suspended in EtOAc (1.5 mL) in a microwave vial and treated with
excess 1-benzyl-N-methylpiperidin-4-amine (430 μL, 2.1 mmol). The
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vial was sealed and irradiated for 90 min at 180 °C. After workup, the
crude product was purified by flash column chromatography (EtOAc;
100%) to give (S)-2-(1-(2-((1-benzylpiperidin-4-yl)(methyl)amino)-
thieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)acetonitrile, as a colorless
oil (126 mg, 0.28 mmol, 80%). 1H NMR (400 MHz, CDCl3) δ 7.60
(d, J = 5.4 Hz, 1H), 7.42−7.23 (m, 5H), 7.16 (d, J = 5.4 Hz, 1H),
4.68 (m, 3H), 4.09 (m, 1H), 3.99−3.88 (m, 1H), 3.57 (s, 2H), 3.11
(m, 1H), 3.08 (s, 3H), 3.04 (m, 2H), 2.81−2.69 (m, 1H), 2.33−2.08
(m, 4H), 1.99−1.84 (m, 2H), 1.70 (m, 2H).
The intermediate (126 mg, 0.28 mmol, 0.28 mmol) was
debenzylated using 1-chloroethyl chloroformate according to general
method C. After workup, the crude product was purified by flash
column chromatography (CH2Cl2/MeOH/aq. NH3; 97:3:0.5−
95:5:0.5−90:10:1) to give the title compound (44) as a colorless
oil (25 mg, 0.070 mmol, 25%). LC-MS Rt = 7.6 min; MH
+ 357; 1H
NMR (400 MHz, CDCl3) δ 7.58 (d, J = 5.4 Hz, 1H), 7.14 (d, J = 5.4
Hz, 1H), 4.78−4.69 (m, 1H), 4.69−4.62 (m, 1H), 4.10−4.04 (m,
1H), 3.96−3.86 (m, 1H), 3.24−3.16 (m, 2H), 3.13−3.06 (m, 1H),
3.04 (s, 3H), 2.84−2.76 (m, 2H), 2.76−2.69 (m, 1H), 2.28−2.07
(m, 2H), 2.23−2.06 (m, 3H), 1.80−1.69 (m, 4H); ESI HRMS,
found 357.1861 (C18H25N6S [M + H]
+ requires 357.1861).
(S)-2-(1-(2-((3-(Dimethylamino)propyl)(methyl)amino)thieno-
[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)acetonitrile (45). According to
general method B for C2 displacements, intermediate IM13 (15 mg,
0.042 mmol) was suspended in EtOAc (1 mL) in a microwave vial
and treated with excess N,N,N′-trimethyl-1,3-propane-diamine (100
μL, 0.78 mmol). The vial was sealed and irradiated for 30 min at 150
°C. After workup, the crude product was purified by reverse-phase
HPLC (20−98% MeOH/water/0.1% formic acid) to give the title
compound (45) as a formate salt (6.3 mg, 0.016 mmol, 37%). LC-
MS Rt = 7.8 min; MH
+ 359; 1H NMR (400 MHz, CD3OD) δ 8.38
(s, 1H), 8.00 (d, J = 5.5 Hz, 1H), 7.31 (d, J = 5.5 Hz, 1H), 4.79−
4.73* (m, 2H), 4.16−4.10 (m, 1H), 4.05−3.97 (m, 1H), 3.80−3.67
(m, 2H), 3.21 (s, 3H), 3.16−3.11 (m, 2H), 3.08−3.05 (m, 1H), 2.88
(s, 6H), 2.40−2.23 (m, 2H), 2.22−2.05 (m, 4H). ESI HRMS, found
359.2021, (C18H27N6S [M + H]
+ requires 359.2018). * Partially
obscured by the H2O signal.
N4-Ethyl-N2,N4-dimethyl-N2-(1-methylpiperidin-4-yl)thieno[3,2-
d]pyrimidine-2,4-diamine (46). According to general method D for
reductive amination, N4-ethyl-N2,N4-dimethyl-N2-(piperidin-4-yl)-
thieno[3,2-d]pyrimidine-2,4-diamine (47, 18 mg, 0.045 mmol) was
dissolved in DCE (5 mL) and treated with paraformaldehyde (6.0
mg, 0.2 mmol) and sodium triacetoxyborohydride (85 mg, 0.4
mmol). After workup, the crude product was purified by reverse-
phase HPLC (20−98% MeOH/water/0.1% formic acid), partially
evaporated, and then lyophilized to give the title compound (46) as a
di-formate salt (14.0 mg, 0.034 mmol, 58%). LC-MS Rt = 7.8 min;
MH+ 320; 1H NMR (400 MHz, CD3OD) δ 8.50 (br s, 2H), 7.88 (d,
J = 5.5 Hz, 1H), 7.17 (d, J = 5.5 Hz, 1H), 4.93−4.90* (m, 1H), 3.85
(q, J = 7.0 Hz, 2H), 3.60−3.53 (m, 2H), 3.40 (s, 3H), 3.16−3.08 (m,
2H), 3.07 (s, 3H), 2.85 (s, 3H), 2.17 (dq, J = 13.3, 3.9 Hz, 2H),
2.00−1.93 (m, 2H), 1.29 (t, J = 7.0 Hz, 3H); ESI HRMS, found
320.1910, (C16H26N5S [M + H]
+ requires 320.1909). *Partially
obscured by the H2O signal.
N4-Ethyl-N2,N4-dimethyl-N2-(piperidin-4-yl)thieno[3,2-d]-
pyrimidine-2,4-diamine (47). A solution of N2-(1-benzylpiperidin-4-
yl)-N4-ethyl-N2,N4-dimethylthieno[3,2-d]pyrimidine-2,4-diamine (49,
31 mg, 0.078 mmol) was debenzylated using 1-chloroethyl
chloroformate (20 μL) according to general method C. After
workup, the crude product was purified by reverse-phase HPLC
(20−98% MeOH/water/0.1% formic acid) to give the title
compound (47) as a di-formate salt (22 mg, 0.055 mmol, 71%).
LC-MS Rt = 7.9 min; MH
+ 331; 1H NMR (400 MHz, CD3OD) δ
8.26 (s, 1H), 8.12 (d, J = 5.5 Hz, 1H), 7.37 (d, J = 5.5 Hz, 1H),
4.95−4.90* (m, 1H), 3.93 (q, J = 7.0 Hz, 2H), 3.60−3.54 (m, 2H),
3.50 (s, 3H), 3.27−3.18 (m, 2H), 3.14 (s, 3H), 2.15 (dq, J = 13.1,
4.2 Hz, 2H), 2.10−2.00 (m, 2H), 1.35 (t, J = 7.0 Hz, 3H); ESI
HRMS, found 306.1750 (C15H24N5S [M + H]
+ requires 306.1752).
*Partially obscured by the H2O signal.
N2-(3-(Dimethylamino)propyl)-N4-ethyl-N2,N4-dimethylthieno-
[3,2-d]pyrimidine-2,4-diamine (48). According to general method B
for C2 displacements, intermediate IM14 (21 mg, 0.083 mmol) was
suspended in EtOAc (1 mL) in a microwave vial and treated with
excess N,N,N′-trimethyl-1,3-propane-diamine (117 μL, 0.8 mmol).
The vial was sealed and irradiated for 30 min at 120 °C. After
workup, the crude product was purified by reverse-phase HPLC
(33−98% MeOH/water/0.1% formic acid) to give the title
compound (48) (13 mg, 0.042 mmol, 51%). LC-MS Rt = 7.7 min;
MH+ 308; 1H NMR (400 MHz, CD3OD) δ 7.75 (d, J = 5.5 Hz, 1H),
7.12 (d, J = 5.5 Hz, 1H), 3.80 (q, J = 7.1 Hz, 2H), 3.66 (t, J = 7.1
Hz, 2H), 3.34 (s, 3H), 3.13 (s, 3H), 2.43−2.36 (m, 2H), 2.28 (s,
6H), 1.90−1.81 (m, 2H), 1.26 (t, J = 7.1 Hz, 3H); ESI HRMS,
found 308.1911 (C15H26N5S [M + H]
+ requires 308.1909).
N2-(1-Benzylpiperidin-4-yl)-N4-ethyl-N2,N4-dimethylthieno[3,2-
d]pyrimidine-2,4-diamine (49). According to general method B for
C2 displacements, intermediate IM14 (140 mg, 0.61 mmol) was
suspended in EtOAc (1.5 mL) in a microwave vial and treated with
excess 1-benzyl-N-methylpiperidin-4-amine (500 mg, 2.4 mmol). The
vial was sealed and irradiated for 90 min at 180 °C. After workup, the
crude product was purified by flash column chromatography (EtOAc;
100%) to give the title compound (49) as a colorless oil (87 mg,
0.22 mmol, 36%). LC-MS Rt = 9.0 min; MH
+ 396; 1H NMR (400
MHz, CDCl3) δ 7.51 (d, J = 5.7 Hz, 1H), 7.36−7.22 (m, 5H), 7.12
(d, J = 5.7 Hz, 1H), 4.72−4.63 (m, 1H), 3.74 (q, J = 7.0 Hz, 2H),
3.52 (s, 2H), 3.30 (s, 3H), 3.06 (s, 2H), 3.02−2.96 (m, 2H), 2.13
(dt, J = 11.8, 2.5 Hz, 2H), 1.86 (dq, J = 12.1, 3.8 Hz, 2H), 1.72−1.76
(m, 2H), 1.24 (t, J = 7.0 Hz, 3H). ESI HRMS, found 396.2224
(C22H30N5S [M + H]
+ requires 396.2223).
3-((6-(tert-Butyl)-2-(methyl(1-methylpiperidin-4-yl)amino)-
thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (50). In-
termediate IM15 (0.064 g, 0.21 mmol) was suspended in n-BuOH
(1. mL) in a microwave vial and treated with excess 1-benzyl-N-
methylpiperidin-4-amine (169 mg, 0.84 mmol). The vial was sealed
and irradiated for 2 h at 200 °C. After workup, the crude product
was purified by flash column chromatography (MeOH/CH2Cl2, 1:9)
to give 3-((2-((1-benzylpiperidin-4-yl)(methyl)amino)-6-(tert-butyl)-
thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile as a yel-
low oil (58 mg, 0.12 mmol, 58%). This was debenzylated using 10%
Pd/C (13 mg) and ammonium formate (77 mg) in EtOH (2.0 mL).
The crude product (0.024 g, 0.06 mmol) was then methylated using
formaldehyde (6 mg, 0.29 mmol), sodium triacetoxyborohydride (27
mg, 0.125 mmol), and acetic acid (7.1 μL, 0.125 mmol) according to
general method D to give the product (9.0 mg, 0.020 mmol, 10%)
after purification by reverse-phase HPLC (30−98% MeOH/water/
0.1% formic acid). LC-MS Rt = 8.3 min; MH
+ 401; 1H NMR
(CDCl3) δ 8.45 (s, 1.5H), 6.99 (s, 1H), 5.00−4.92 (m, 1H)*, 4.08
(t, J = 6.6 Hz, 2H), 3.64−3.58 (m, 2H), 3.55 (s, 3H), 3.23−3.16 (m,
2H), 3.07 (s, 3H), 2.91 (t, J = 6.7 Hz, 2H), 2.89 (s, 3H), 2.22−2.12
(m, 2H), 2.01−1.97 (m, 2H), 1.46 (s, 9H);. ESI HRMS, found
401.2491 (C21H33N6S [M + H]
+ requires 401.2487). *Partially
obscured by the water signal.
3-((6-(tert-Butyl)-2-((3-(dimethylamino)propyl)(methyl)amino)-
thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (51). In-
termediate IM15 (42 mg, 0.14 mmol) was suspended in DMA (1.0
mL) in a microwave vial and treated with excess N,N,N′-trimethyl-
1,3-propane-diamine (80 μL, 0.55 mmol). The vial was sealed and
heated for 24 h at 120 °C. The reaction mixture was partitioned
between EtOAc (20 mL) and 1 M NaOH solution (10 mL), and
then the aqueous layer was re-extracted with EtOAc (10 mL). The
combined organic layers were dried (Na2SO4) and concentrated
under reduced pressure. The crude product was purified by reverse-
phase HPLC (30−98% MeOH/water/0.1% formic acid) to give the
title compound (51) (4.0 mg, 0.01 mmol, 7%). LC-MS Rt = 10.7
min (30−98% MeCN/water/0.1% formic acid); 1H NMR (CDCl3)
δ 6.99 (s, 1H), 4.08 (t, J = 6.6 Hz, 2H), 3.72 (t, J = 6.3 Hz, 2H),
3.55 (s, 3H), 3.18 (s, 3H), 3.11 (t, J = 7.1 Hz, 2H), 2.91 (t, J = 6.6
Hz, 2H), 2.88 (s, 6H), 2.13−2.07 (m, 2H), 1.45 (s, 9H); ESI
HRMS, found 389.2501 (C20H33N6S [M + H]
+, requires 389.2487).
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3-((6-(tert-Butyl)-2-(methyl(1-methylpyrrolidin-3-yl)amino)-
thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (52).
According to general method D for reductive amination, ((6-(tert-
butyl)-2-(methyl(pyrrolidin-3-yl)amino)thieno[3,2-d]pyrimidin-4-
yl)(methyl)amino)propanenitrile (53, 8 mg, 0.02 mmol) was
methylated using paraformaldehyde (∼2 mg, 4.0 equiv) and sodium
triacetoxyborohydride (17 mg, 4.0 equiv) in DCE (5.0 mL). After
workup, the crude product was purified by reverse-phase HPLC
(20−98% MeOH/water/0.1% formic acid), partially evaporated, and
then lyophilized to give the title compound as a colorless formate salt
(3.1 mg, 0.007 mmol, 36%). LC-MS Rt = 9.4 min; MH
+ 387; 1H
NMR (400 MHz, CD3OD) δ 8.54 (s, 3H), 7.01 (s, 1H), 5.13−5.05
(m, 1H), 4.05 (t, J = 6.6 Hz, 2H), 3.66−3.58 (m, 1H), 3.53 (s, 3H),
3.45−3.39 (m, 1H), 3.30−3.16 (m, 1H), 3.18 (s, 3H), 3.11−3.03
(m, 1H), 2.91−2.85 (m, 5H), 2.50−2.39 (m, 1H), 2.27−2.13 (m,
1H), 1.45 (s, 9H); ESI HRMS, found 387.2336 (C20H31N6S [M +
H]+ requires 387.2331).
3-((6-(tert-Butyl)-2-(methyl(pyrrolidin-3-yl)amino)thieno[3,2-d]-
pyrimidin-4-yl)(methyl)amino)propanenitrile (53). A solution of 3-
((2-((1-benzylpyrrolidin-3-yl)(methyl)amino)-6-(tert-butyl)thieno-
[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (54, 96 mg,
0.21 mmol) in EtOH (10 mL) was treated with an excess of
ammonium formate (126 mg, 2 mmol) and a catalytic quantity of
10% Pd/C. The mixture was heated under reflux overnight, cooled to
room temperature, filtered through celite, and evaporated under
reduced pressure. The crude product was purified by reverse-phase
HPLC (33−98% MeOH/water/0.1% formic acid), partially evapo-
rated, and then lyophilized to give the title compound (53) as a
colorless formate salt (9.7 mg, 0.023 mmol, 11%). LC-MS Rt = 9.6
min; MH+ 373; 1H NMR (400 MHz, CD3OD) δ 8.42 (s, 2H), 7.05
(s, 1H), 5.16−5.09 (m, 1H), 4.05 (t, J = 6.6 Hz, 2H), 3.72−3.76 (m,
1H), 3.53 (s, 3H), 3.49−3.38 (m, 2H), 3.30−3.23 (m, 1H), 3.18 (s,
3H), 2.88 (t, J = 6.6 Hz, 2H), 2.42−2.32 (m, 1H), 2.27−2.16 (m,
1H), 1.44 (s, 9H); ESI HRMS, found 373.2188 (C19H29N6S [M +
H]+, requires 373.2174).
3-((2-((1-Benzylpyrrolidin-3-yl)(methyl)amino)-6-(tert-butyl)-
thieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (54).
According to general method B for C2 displacements, intermediate
IM15 (0.10 g, 0.32 mmol) was suspended in EtOAc (1.5 mL) in a
microwave vial and treated with excess 1-benzyl-N-methylpyrrolidin-
3-amine (250 μL, 1.3 mmol). The vial was sealed and irradiated for
90 min at 180 °C. After workup, the crude product was purified by
flash column chromatography (EtOAc/hexane; 1:1 and then 1:0) to
give the title compound (54) as a colorless oil (96 mg, 0.21 mmol,
65%). LC-MS Rt = 10.5 min; MH
+ 463; 1H NMR (400 MHz,
CDCl3) δ 7.38−7.22 (m, 5H), 6.94 (s, 1H), 5.55−5.46 (m, 1H),
3.95 (t, J = 6.6 Hz, 2H), 3.69 (d, J = 12.9 Hz, 1H), 3.57 (d, J = 12.9
Hz, 1H), 3.51 (s, 3H), 3.12 (s, 3H), 2.90−2.84 (m, 1H), 2.76 (t, J =
6.7 Hz, 2H), 2.70−2.56 (m, 2H), 2.48−2.36 (m, 1H), 2.26−2.16 (m,
1H), 1.98−1.82 (m, 1H), 1.42 (s, 9H); ESI HRMS found 463.2639
(C26H35N6S, [M + H]
+, requires 463.2644).
3-((6-Bromo-2-(methyl(1-methylpiperidin-4-yl)amino)-
quinazolin-4-yl)(methyl)amino)propanenitrile (55). 3-((6-Bromo-2-
chloroquinazolin-4-yl)(methyl)amino)propanenitrile IM16 (25.0 mg,
0.077 mmol) and N,1-dimethylpiperidin-4-amine (39 mg, 0.31
mmol) were dissolved in n-BuOH (2.0 mL) and heated at 150 °C
for 3 h. After cooling, the solvent was concentrated in vacuo and the
residue was purified by reverse-phase HPLC (50−98% MeOH/
water/0.1% formic acid) to give the title compound 55 as a 50%
formate salt (3.4 mg, 0.008 mmol, 10%). LC-MS Rt 6.73 min;
1H
NMR (400 MHz, CDCl3) δ 8.50 (0.5H, s), 7.95 (1H, d, J = 2.2 Hz),
7.57 (1H, dd, J = 9.0, 2.2 Hz), 7.39 (1H, d, J = 9.0 Hz), 4.97 (1H,
m), 3.94 (2H, t, J = 7.0 Hz), 3.49−3.44 (5H, m), 3.09 (3H, s), 2.86
(2H, t, J = 7.0 Hz), 2.85−2.78 (2H, m), 2.68 (s, 3H), 2.45−2.36 (m,
2H), 1.86−1.82 (2H, m); ESI HRMS, found 417.1402
(C19H26N6
79Br [M + H]+, requires 417.1402).
3-((6-Bromo-2-((3-(dimethylamino)propyl)(methyl)amino)-
quinazolin-4-yl)(methyl)amino)propanenitrile (56). 3-((6-Bromo-2-
chloroquinazolin-4-yl)(methyl)amino)propanenitrile IM16 (50.0 mg,
0.15 mmol) and N1,N1,N3-trimethylpropane-1,3-diamine (90 μL,
0.61 mmol) were dissolved in EtOAc (1.5 mL) and heated at 180 °C
in a microwave for 90 min. After cooling, the solution was washed
with H2O, dried over MgSO4, and concentrated in vacuo to give a
yellow oil, which was purified by reverse-phase HPLC (5−98%
MeOH/water/0.1% formic acid) to give the title compound 56 as a
formate salt (11 mg, 0.024 mmol, 16%). LC-MS Rt 8.29 min;
1H
NMR (400 MHz, CDCl3) δ 8.53 (s, 1H), 7.93 (1H, d, J = 2.2 Hz),
7.55 (1H, dd, J = 9.0, 2.2 Hz), 7.35 (1H, d, J = 9.0 Hz), 3.93 (2H, t,
J = 6.9 Hz), 3.73 (2H, t, J = 7.1 Hz), 3.44 (3H, s), 3.18 (3H, s), 2.87
(2H, t, J = 6.9 Hz), 2.74−2.70 (2H, m), 2.51 (6H, s), 2.02−1.95 (m,
2H); 13C NMR (101 MHz, CDCl3) δ 168.6, 162.7, 158.2, 153.8,
135.7, 128.1, 127.8, 118.5, 112.4, 112.3, 56.1, 48.7, 47.0, 43.8, 41.8,
35.3, 24.3, 15.6; ESI HRMS, found 405.1391 (C18H26N6
79Br [M +
H]+, requires 405.1402).
3-((6-Bromo-2-(methyl(1-methylpyrrolidin-3-yl)amino)-
quinazolin-4-yl)(methyl)amino)propanenitrile (57). 3-((6-Bromo-2-
chloroquinazolin-4-yl)(methyl)amino)propanenitrile IM16 (25.0 mg,
0.077 mmol) and N1-dimethylpyrrolidin-3-amine (50 μL, 0.38
mmol) were dissolved in n-BuOH (2.0 mL) and heated at reflux
for 3 h. After cooling, the solvent was concentrated in vacuo and the
residue was dissolved in 5% MeOH and 95% H2O to give a
suspension. After filtration, the residual solid was purified by reverse-
phase HPLC (50−98% MeOH/water/0.1% formic acid) to give the
title compound 57 as a di-formate salt (11 mg, 0.024 mmol, 32%).
LC-MS Rt 6.71 min;
1H NMR (400 MHz, CDCl3) δ 8.41 (2H, s),
7.99 (1H, d, J = 2.2 Hz), 7.59 (1H, dd, J = 8.9, 2.2 Hz), 7.37 (1H, d,
J = 9.0 Hz), 5.63 (1H, p, J = 8.6 Hz), 3.97 (2H, td, J = 6.6, 2.0 Hz),
3.61−3.52 (1H, m), 3.49 (3H, s), 3.47−3.29 (3H, m), 3.17 (3H, s),
2.87 (2H, t, J = 6.6 Hz), 2.84 (3H, s), 2.37−2.31 (2H, m); 13C NMR
(101 MHz, CDCl3) δ 166.9, 162.4, 157.6, 153.0, 136.0, 128.0, 127.8,
118.5, 113.1, 112.7, 55.0, 54.7, 54.6, 48.8, 42.1, 41.1, 27.4, 15.7; ESI
HRMS, found 403.1228 (C18H24N6
79Br [M + H]+, requires
403.1246).
3-((6-Methoxy-2-(methyl(1-methylpiperidin-4-yl)amino)-
quinazolin-4-yl)(methyl)amino)propanenitrile (58). 3-((2-Chloro-
6-methoxyquinazolin-4-yl)(methyl)amino)propanenitrile IM17 (50.0
mg, 0.18 mmol) and N,1-dimethylpiperidin-4-amine (92 mg, 0.72
mmol) were dissolved in n-BuOH (2.0 mL) and heated at 120 °C for
3 h. After cooling, the reaction was concentrated in vacuo and the
solid was dissolved in EtOAc and washed with H2O (5×). The
solution was concentrated again, and the residue was purified by
reverse-phase HPLC (50−98% MeOH/water/0.1% formic acid) to
give the title compound 58 as a di-formate salt (2.0 mg, 0.004 mmol,
2%). LC-MS Rt 6.18 min;
1H NMR (400 MHz, MeOD) δ 8.36 (s,
2H), 7.57 (d, J = 9.1 Hz, 1H), 7.45 (d, J = 2.7 Hz, 1H), 7.39 (dd, J =
9.1, 2.7 Hz, 1H), 4.99−4.96 (1H, m)*, 4.09 (t, J = 6.8 Hz, 2H), 3.89
(s, 3H), 3.56 (s, 3H), 3.56−3.51 (2H, m), 3.13 (s, 3H), 3.13−3.03
(2H, m); 3.02 (t, J = 6.8 Hz, 3H), 2.82 (s, 3H), 2.19−2.09 (2H, m),
2.01−1.95 (2H, m); ESI HRMS, found 369.2393 (C20H29N6O [M +
H]+, requires 369.2403). *Obscured by the H2O signal; the presence
was confirmed by COSY coupling to multiplet at 2.19−2.09 Hz.
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-6-methoxyqui-
nazolin-4-yl)(methyl)amino)propanenitrile (59). 3-((2-Chloro-6-
methoxyquinazolin-4-yl)(methyl)amino)propanenitrile IM17 (50
mg, 0.18 mmol) and N1,N1,N3-trimethylpropane-1,3-diamine (106
μL, 0.72 mmol) were dissolved in EtOAc and heated at 180 °C in a
microwave for 90 min. After cooling, the solution was washed with
H2O and then brine, dried over MgSO4, and concentrated in vacuo to
give a yellow oil, which was purified by reverse-phase HPLC (5−98%
MeOH/water/0.1% formic acid) to give the title compound 59 (18
mg, 0.065 mmol, 36%). LC-MS Rt 7.22 min;
1H NMR (400 MHz,
CDCl3) δ 7.47 (1H, d, J = 9.1 Hz), 7.24 (1H, dd, J = 9.1, 2.8 Hz),
7.16 (1H, d, J = 2.8 Hz), 3.89 (2H, t, J = 6.9 Hz), 3.85 (3H, s), 3.72
(2H, t, J = 7.1 Hz), 3.38 (3H, s), 3.19 (3H, s), 2.87 (2H, t, J = 6.9
Hz), 2.65 (2H, t, J = 7.7 Hz), 2.46 (6H, s), 2.01−1.90 (2H, m); 13C
NMR (101 MHz, CDCl3) δ 163.7, 157.5, 153.3, 150.2, 127.6, 123.9,
118.7, 111.3, 105.4, 56.5, 55.9, 48.7, 47.1, 44.3, 41.3, 35.4, 24.7, 15.8;
ESI HRMS, found 357.2386 (C19H29N6O [M + H]
+, requires
357.2403).
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3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-6-phenylqui-
nazolin-4-yl)(methyl)amino)propanenitrile (60). 3-((2-Chloro-6-
phenylquinazolin-4-yl)(methyl)amino)propanenitrile IM18 (10 mg,
0.031 mmol) and N1,N1,N3-trimethylpropane-1,3-diamine (18 μL,
0.12 mmol) were dissolved in n-BuOH (0.5 mL) and heated at 120
°C for 4 h. After cooling, the solution was diluted with EtOAc,
washed with H2O and then brine, dried over MgSO4, and
concentrated in vacuo. The residue was purified by reverse-phase
HPLC (method C) to give the title compound 60 as a 0.5 formate
salt (8 mg, 0.018 mmol, 61%). LC-MS Rt 8.87 min;
1H NMR (400
MHz, CDCl3) δ 8.55 (s, 0.5H), 8.01 (d, J = 2.0 Hz, 1H), 7.79 (dd, J
= 8.7, 2.1 Hz, 1H), 7.61−7.54 (m, 3H), 7.45 (dd, J = 8.4, 7.0 Hz,
2H), 7.37−7.31 (m, 1H), 3.97 (t, J = 6.9 Hz, 2H), 3.78 (t, J = 7.0
Hz, 2H), 3.50 (s, 3H), 3.22 (s, 3H), 2.90 (t, J = 6.9 Hz, 2H), 2.75 (t,
J = 7.8 Hz, 2H), 2.53 (s, 6H), 2.09−1.97 (m, 2H); 13C NMR (101
MHz, CDCl3) δ 168.7, 163.9, 158.2, 154.3, 140.9, 133.2, 132.1,
129.1, 127.2, 126.9, 126.6, 123.7, 118.6, 111.4, 56.2, 48.7, 47.0, 43.9,
41.9, 35.4, 24.5, 15.7; ESI HRMS, found 403.2619 (C24H31N6 [M +
H]+, requires 403.2610).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-6-(o-tolyl)-
quinazolin-4-yl)(methyl)amino)propanenitrile (61). 3-((2-Chloro-
6-(o-tolyl)quinazolin-4-yl)(methyl)amino)propanenitrile IM19 (30
mg, 0.089 mmol) and N1,N1,N3-trimethylpropane-1,3-diamine (52
μL, 0.36 mmol) were dissolved in n-BuOH (0.5 mL) and heated at
120 °C for 4 h. After cooling, the solution was diluted with EtOAc,
washed with H2O and then brine, dried over MgSO4, and
concentrated in vacuo. The residue was purified by reverse-phase
HPLC (50−98% MeOH/water/0.1% formic acid) to give the title
compound 61 as a di-formate salt (6.2 mg, 0.012 mmol, 14%). LC-
MS Rt 9.04 min (5−98% MeCN/water/0.1% formic acid); MH
+
417.4; 1H NMR (400 MHz, CDCl3) δ 8.40 (3H, br s), 7.85 (d, J =
8.6 Hz, 1H), 7.83 (d, J = 1.9 Hz, 1H), 7.63 (dd, J = 8.6, 1.8 Hz, 1H),
7.32−7.27 (m, 3H), 7.23−7.19 (m, 1H), 4.08 (t, J = 6.7 Hz, 2H),
3.87 (t, J = 7.1 Hz, 2H), 3.60 (s, 3H), 3.29 (s, 3H), 3.20−3.16 (m,
2H), 2.93 (t, J = 6.6 Hz, 2H), 2.80 (s, 6H), 2.27 (s, 3H), 2.20 (p, J =
7.6, 6.9 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.5, 162.8,
154.3, 140.3, 136.4, 135.7, 135.3, 130.7, 129.8, 127.9, 126.2, 126.0,
121.7, 117.9, 110.2, 54.7, 49.1, 47.1, 42.7, 42.3, 36.1, 23.0, 20.5, 15.5;
ESI HRMS, found 417.2771 (C25H33N6 [M + H]
+, requires
417.2767).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-6-(4-methoxy-
2-methylphenyl)quinazolin-4-yl)(methyl)amino)propanenitrile
(62). 3-((2-Chloro-6-(4-methoxy-2-methylphenyl)quinazolin-4-yl)-
(methyl)amino)propanenitrile IM20 (22 mg, 0.060 mmol) and
N1,N1,N3-trimethylpropane-1,3-diamine (36 μL, 0.24 mmol) were
dissolved in n-BuOH (1 mL) and heated at 120 °C for 4 h. After
cooling, the solution was diluted with EtOAc, washed with H2O and
then brine, dried over MgSO4, and concentrated in vacuo. The
residue was purified by reverse-phase HPLC (50−98% MeOH/
water/0.1% formic acid) to give the title compound 62 as a formate
salt (5.5 mg, 0.011 mmol, 19%). LC-MS Rt 9.49 min; MH
+ 447.4;
1H NMR (400 MHz, CDCl3) δ 8.35 (1H, s), 8.06 (m, 1H), 7.79 (d,
J = 1.8 Hz, 1H), 7.61 (dd, J = 8.7, 1.9 Hz, 1H), 7.14 (d, J = 8.3 Hz,
1H), 6.85−6.81 (m, 2H), 4.07 (t, J = 6.6 Hz, 2H), 3.91 (t, J = 7.1
Hz, 2H), 3.85 (s, 3H), 3.59 (s, 3H), 3.29 (s, 3H), 3.24−3.19 (s, 2H),
2.92 (t, J = 6.8 Hz, 2H), 2.81 (s, 6H), 2.26 (m, 5H).
3-((2-((3-(Dimethylamino)propyl)(methyl)amino)-7-methoxyqui-
nazolin-4-yl)(methyl)amino)propanenitrile (63). 3-((2-Chloro-7-
methoxyquinazolin-4-yl)(methyl)amino)propanenitrile (IM21) and
N1,N1,N3-trimethylpropane-1,3-diamine were dissolved in n-BuOH
(1 mL) and heated at 120 °C for 4 h. After cooling, the solution was
diluted with EtOAc, washed with H2O and then brine, dried over
MgSO4, and concentrated in vacuo. The residue was purified by
reverse-phase HPLC (50−98% MeOH/water/0.1% formic acid) to
give product 63 as a formate salt (17 mg, 0.042 mmol). LC-MS Rt
8.18 min; MH+ 357.3; 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1H),
7.85 (br s, 2H), 7.74 (d, J = 9.2 Hz, 1H), 6.99 (d, J = 2.6 Hz, 1H),
6.70 (dd, J = 9.2, 2.6 Hz, 1H), 3.95 (t, J = 6.8 Hz, 2H), 3.88 (s, 3H),
3.77 (t, J = 7.0 Hz, 2H), 3.45 (s, 3H), 3.20 (s, 3H), 2.99−2.92 (m,
2H), 2.86 (t, J = 6.8 Hz, 2H), 2.67 (s, 3H), 2.12−2.03 (m, 2H); 13C
NMR (101 MHz, CDCl3) δ 167.8, 163.4, 163.0, 157.3, 155.1, 127.1,
118.5, 112.8, 105.2, 104.2, 55.7, 55.3, 48.7, 46.8, 42.9, 41.9, 35.5,
23.4, 15.8; ESI HRMS, found 357.2397 (C19H29N6O [M + H]
+,
requires 357.2403).
4-(Ethyl(methyl)amino)-2-(methyl(1-methylpiperidin-4-yl)-
amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)quinazoline-6-sulfona-
mide (64). According to general method D for reductive amination,
4-(ethyl(methyl)amino)-2-(methyl(piperidin-4-yl)amino)-N-(1,3,5-
trimethyl-1H-pyrazol-4-yl)quinazoline-6-sulfonamide (67) was re-
acted with paraformaldehyde. After purification by reverse-phase
HPLC, product 64 was obtained (1.2 mg, 0.002 mmol, 31%). LC-
MS Rt 8.11 min (83%); MH
+ 501.6; 1H NMR (400 MHz, CDCl3) δ
8.19 (br s, 3H), 7.97 (d, J = 1.9 Hz, 1H), 7.83 (dd, J = 8.9, 1.9 Hz,
1H), 7.49 (d, J = 9.0 Hz, 1H), 5.08−4.95 (m, 1H), 3.60 (s, 3H),
3.59−3.50 (m, 4H), 3.25−3.15 (m, 2H), 3.15 (s, 3H), 3.11 (s, 3H),
2.98 (s, 3H), 2.18−2.03 (m, 2H), 1.96 (s, 3H), 1.58 (s, 3H), 1.34−
1.26 (m, 7H); ESI HRMS, found 501.2746 (C24H37N8O2S [M +
H]+, requires 501.2760).
4-(Ethyl(methyl)amino)-2-(methyl(piperidin-4-yl)amino)-N-
(1,3,5-trimethyl-1H-pyrazol-4-yl)quinazoline-6-sulfonamide (65).
2-Chloro-4-(ethyl(methyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-
yl)quinazoline-6-sulfonamide (47 mg, 0.116 mmol, 1.0 equiv) and N-
benzyl-N-methylpiperidin-4-amine (10 equiv) were combined in n-
BuOH (1.0 mL) and stirred at 120 °C overnight. The reaction
mixture was then concentrated in vacuo, and the crude residue was
purified by flash column chromatography (CHCl3/MeOH/aq. NH3;
90:10:0.1) to give 2-((1-benzylpiperidin-4-yl)(methyl)amino)-4-
(ethyl(methyl)amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-
quinazoline-6-sulfonamide. This intermediate was debenzylated by
dissolving it in 1 mL EtOH with ammonium formate (74 mg, 1.17
mmol, 10 equiv) and 10% Pd/C (13 mg) and then stirred at 80 °C
overnight. The reaction mixture was then filtered through celite and
concentrated in vacuo, before purification by reverse-phase HPLC to
give product 65 as a light yellow oil (3.7 mg, 0.008 mmol, 7%). 1H
NMR (400 MHz, CDCl3) δ
1H NMR (400 MHz, CDCl3) δ 8.25
(br, s, 3H), 7.99 (d, J = 1.9 Hz, 1H), 7.87 (dd, J = 8.9, 1.9 Hz, 1H),
7.55 (d, J = 8.8 Hz, 1H), 5.07−4.98 (m, 1H), 3.62 (s, 3H), 3.61−
3.51 (m, 4H), 3.22−3.18 (m, 2H), 3.19 (s, 3H), 3.14 (s, 3H), 2.17−
2.03 (m, 2H), 2.02−1.97 (m, 5H), 1.62 (s, 3H), 1.30 (t, J = 7.0 Hz,
3H).
2-((3-(Dimethylamino)propyl)(methyl)amino)-4-(ethyl(methyl)-
amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)quinazoline-6-sulfona-
mide (66). 2-Chloro-4-(ethyl(methyl)amino)quinazoline-6-sulfonyl
chloride (50 mg, 0.156 mmol), 1,3,5-trimethyl-1H-pyrazol-4-amine
(22 mg, 0.172 mmol), and triethylamine (43 μL, 0.312 mmol) were
dissolved in DMF (1.0 mL). After purification by flash column
chromatography, 2-chloro-4-(ethyl(methyl)amino)-N-(1,3,5-trimeth-
yl-1H-pyrazol-4-yl)quinazoline-6-sulfonamide and N,N,N-trimethyl-
propane-1,3-diamine (58 μL) were combined in n-BuOH (1.0 mL)
and stirred at 120 °C overnight. The reaction mixture was then
concentrated in vacuo and purified by reverse-phase HPLC to give
the title compound 66 (6 mg, 0.012 mmol, 12%). 1H NMR (400
MHz, CDCl3) δ 8.32 (br, s, 2H), 8.00 (d, J = 2.0 Hz, 1H), 7.84 (dd,
J = 8.9, 2.0 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 3.78 (t, J = 6.4 Hz,
2H), 3.60 (s, 3H), 3.55 (q, J = 7.0 Hz, 2H), 3.22 (s, 3H), 3.18 (s,
3H), 3.10 (t, J = 7.0 Hz, 2H), 2.86 (s, 6H), 2.11 (qt, J = 6.5 Hz,
2H), 1.96 (s, 3H), 1.58 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H); ESI
HRMS, found 489.2739 (C23H37N8O2S [M + H]
+, requires
489.2760).
4-(Ethyl(methyl)amino)-2-(methyl(1-methylpyrrolidin-3-yl)-
amino)-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)quinazoline-6-sulfona-
mide (67). 2-Chloro-4-(ethyl(methyl)amino)quinazoline-6-sulfonyl
chloride (50 mg, 0.156 mmol), 1,3,5-trimethyl-1H-pyrazol-4-amine
(22 mg, 0.172 mmol), and triethylamine (43 μL, 0.312 mmol) were
dissolved in DMF (1.0 mL). After purification by flash column
chromatography, 2-chloro-4-(ethyl(methyl)amino)-N-(1,3,5-trimeth-
yl-1H-pyrazol-4-yl)quinazoline-6-sulfonamide and N-dimethylpyrroli-
din-3-amine (51 μL) were combined in n-BuOH (1.0 mL) and
stirred at 120 °C overnight. The reaction mixture was then
concentrated in vacuo and purified by reverse-phase HPLC to give
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the title compound 67 (5 mg, 0.01 mmol, 10%). 1H NMR (400
MHz, CDCl3) δ 8.30 (br, s, 2H), 8.02 (d, J = 2.0 Hz, 1H), 7.88 (dd,
J = 8.9, 2.0 Hz, 1H), 7.53 (d, J = 8.8 Hz, 1H), 5.07* (m, 1H), 3.93−
3.80 (m, 1H), 3.68−3.63 (m, 1H), 3.63 (s, 3H), 3.56 (q, J = 6.9 Hz,
2H), 3.46−3.40 (m, 1H), 3.28 (s, 3H), 3.28−2.23 (m, 1H), 3.18 (s,
3H), 3.03 (s, 3H), 2.60−2.51 (m, 1H), 2.35−2.25 (m, 1H), 1.99 (s,
3H), 1.61 (s, 3H), 1.29 (t, J = 7.0 Hz, 3H); ESI HRMS, found
487.2597 (C23H35N8O2S [M + H]
+, requires 487.2604).*Obscured
by the H2O signal.
Synthesis of Intermediate Compounds. 3-((2-Chlorothieno-
[3,2-d]pyrimidin-4-yl)(methyl)amino)propanenitrile (IM1). Using
general method A, 2,4-dichlorothieno[3,2-d]pyrimidine (147 mg,
0.72 mmol) was treated with DIPEA (148 μL, 0.85 mmol) followed
by 3-(methylamino)propanenitrile (67 μL, 0.71 mmol). After
workup, the product, 3-((2-chlorothieno[3,2-d]pyrimidin-4-yl)-
(methyl)amino)propanenitrile (IM1), crystallized on evaporation of
the solvent (173 mg, 0.68 mmol, 95%) without the need for further
purification. Mp 156−158 °C; IR CN ν 2355 cm−1; MS (ESI) 253
(MH+); 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 5.5 Hz, 1H),
7.45 (d, J = 5.5 Hz, 1H), 4.07 (t, J = 6.5 Hz, 2H), 3.73 (s, 3H), 2.90
(t, J = 6.5 Hz, 2H).
3-((2-Chloroquinazolin-4-yl)(methyl)amino)propanenitrile
(IM2). 2,4-Dichloroquinazoline (0.7 g, 3.51 mmol) in DMF (3.0 mL)
was treated with DIPEA (1.3 mL, 2.2 equiv) followed by 3-
(methylamino)propanenitrile (720 μL, 2.2 equiv) and stirred at room
temperature overnight. After the reaction was complete, H2O (50
mL) was added, and the resultant precipitate was collected by
filtration and washed with water, giving the product (0.66 g, 2.68
mmol, 76%) without the need for further purification. 1H NMR (400
MHz, DMSO-d6) δ 8.25 (dd, J = 8.5, 1.3 Hz, 1H), 7.82 (ddd, J = 8.3,
6.9, 1.3 Hz, 1H), 7.69 (dd, J = 8.4, 1.3 Hz, 1H), 7.52 (ddd, J = 8.5,
7.0, 1.4 Hz, 1H), 4.03 (t, J = 6.8 Hz, 2H), 3.52 (s, 3H), 3.01 (t, J =
6.8 Hz, 2H).
3-((2-Chloropyrido[2,3-d]pyrimidin-4-yl)(methyl)amino)-
propanenitrile (IM3). Using general method A, 2,4-dichloropyrido-
[2,3-d]pyrimidine (360 mg, 1.8 mmol) was treated with DIPEA (350
μL, 2.0 mmol) followed by 3-(methylamino)propanenitrile (170 μL,
1.8 mmol). After workup, the crude residue was purified by flash
column chromatography (EtOAc/MeOH; 100:0 and then 90:10) to
give the product, 3-((2-chloropyrido[2,3-d]pyrimidin-4-yl)(methyl)-
amino)propanenitrile (IM3), as a colorless solid (126 mg, 0.51
mmol, 28%). Mp 190−192 °C; 1H NMR (400 MHz, CDCl3), δ 9.06
(dd, J = 4.4, 1.8 Hz, 1H), 8.50 (dd, J = 8.5, 1.8 Hz, 1H), 7.42 (dd, J
= 8.5, 4.4 Hz, 1H), 4.11 (t, J = 6.4 Hz, 2H), 3.72 (s, 3H), 2.99 (t, J =
6.4 Hz, 2H).
3-((2-Chloro-7-methyl-7H-purin-6-yl) (methyl)amino)-
propanenitrile (IM4). A suspension of 2,6-dichloro-7-methyl-7H-
purine (404 mg, 2.1 mmol, 1.0 equiv) in EtOAc/EtOH (10:1, 10
mL) was treated with DIPEA (1.2 equiv) followed by 3-
(methylamino)propanenitrile (215 μL, 2.3 mmol, 1.2 equiv), and
the reaction was heated under reflux for 4 h. The reaction mixture
was cooled to room temperature and then washed with sodium
carbonate solution (1 M, 10 mL), and the aqueous layer was re-
extracted with EtOAc (10 mL). The combined organic layers were
dried (Na2SO4) and concentrated under reduced pressure. The
product, 3-((2-chloro-7-methyl-7H-purin-6-yl)(methyl)amino)-
propanenitrile (IM4), was obtained by flash column chromatography
(EtOAc/MeOH; 95:5 and then 90:10) as a tan solid (300 mg, 1.2
mmol, 57%). 1H NMR (400 MHz, CDCl3), δ 8.05 (s, 1H), 4.08 (s,
3H), 3.86 (t, J = 6.5 Hz, 2H), 3.33 (s, 3H), 2.86 (t, J = 6.5 Hz, 2H).
2-Chloro-N-(2-methoxyethyl)-N-methylthieno[3,2-d]pyrimidin-
4-amine (IM5). Using general method A, 2,4-dichlorothieno[3,2-
d]pyrimidine (146 mg, 0.71 mmol) was treated with DIPEA (148
μL, 0.85 mmol) followed by 2-methoxy-N-methylethanamine (63
mg, 0.71 mmol). After workup, the product, 2-chloro-N-(2-
methoxyethyl)-N-methylthieno[3,2-d]pyrimidin-4-amine (IM5),
crystallized on evaporation of the solvent (185 mg, 0.71 mmol,
quant.) with no need for further purification. Mp 70−72 °C. MS
(ESI) 258 (MH+); 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 5.4
Hz, 1H), 7.35 (d, J = 5.4 Hz, 1H), 3.99 (t, J = 5.4 Hz, 2H), 3.71 (t, J
= 5.4 Hz, 2H), 3.56 (s, 3H), 3.39 (s, 3H).
2-((2-Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)ethanol
(IM6). Using general method A, 2,4-dichlorothieno[3,2-d]pyrimidine
(146 mg, 0.71 mmol) was treated with DIPEA (148 μL, 0.85 mmol)
followed by 2-(methylamino)ethanol (53 mg, 0.71 mmol). After
workup, the product, 2-((2-chlorothieno[3,2-d]pyrimidin-4-yl)-
(methyl)amino)ethanol (IM6), crystallized on evaporation of the
solvent as a colorless solid (158 mg, 0.65 mmol, 91%) with no need
for further purification. Mp 182−183 °C. MS (ESI) 244 (MH+); 1H
NMR (400 MHz, DMSO-d6) δ 8.26 (d, J = 5.8 Hz, 1H), 7.35 (d, J =
5.8 Hz, 1H), 4.94 (br. s, 1H), 3.82 (t, J = 5.8 Hz, 2H), 3.67 (t, J =
5.8 Hz, 2H), 3.42 (s, 3H).
3-((2-Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)propan-
1-ol (IM7). In an adaptation of general method A, 2,4-dichlorothieno-
[3,2-d]pyrimidine (205 mg, 1.0 mmol) was treated with DIPEA (348
μL, 2.0 mmol) followed by 3-(methylamino)propanol (195 μL, 2.0
mmol). After workup, the residue was purified by flash column
chromatography (CH2Cl2/MeOH; 20:1) to give the product, 2-((2-
chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)ethanol (IM7), as
a yellow solid (256 mg, 0.99 mmol, 99%). 1H NMR (400 MHz,
CDCl3) δ 7.80 (d, J = 5.5 Hz, 1H), 7.35 (d, J = 5.5 Hz, 1H), 3.89 (t,
J = 5.5 Hz, 2H), 3.60 (t, J = 5.5 Hz, 2H), 3.50 (s, 3H), 1.94−1.84
(m, 2H).
3-((2-Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)-
propenamide (IM8). 2,4-Dichlorothieno[3,2-d]pyrimidine (50 mg,
0.24 mmol) was dissolved in chlorosulfuric acid (1.0 mL, excess) and
stirred at room temperature for 16 h. The reaction was then cooled
to 0 °C, quenched with H2O, and extracted with EtOAc. The
aqueous layer was neutralized with NaOH, and the resulting
precipitate was collected by filtration to give the product, IM8, as
a white solid (26 mg, 0.096 mmol, 40%). LC-MS Rt = 10.5 min;
MH+ 271/273; 1H NMR (400 MHz, DMSO-d6,) δ 8.29 (d, J = 5.5
Hz, 1H), 7.44 (s, 1H), 7.37 (d, J = 5.6 Hz, 1H), 6.94 (s, 1H), 3.94
(t, J = 7.1 Hz, 2H), 3.39 (s, 3H), 2.48 (d, J = 7.1 Hz, 2H).
N-(2-((2-Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)-
ethyl)-N-methylacetamide (IM9). Step 1: Using an adaptation of
general method A, 2,4-dichlorothieno[3,2-d]pyrimidine (205 mg, 1.0
mmol) was treated with DIPEA (174 μL, 1.0 mmol) followed by
N,N′-dimethylethylenediamine (1.0 mL, 9.3 mmol). After workup,
the crude residue was purified by flash column chromatography
(CH2Cl2/MeOH/aq. NH3; 95:5:0.5−97:3:0.5) to give the product,
N-(2-chlorothieno[3,2-d]pyrimidin-4-yl)-N,N′-dimethylethylenedi-
amine (230 mg, 0.90 mmol, 90%). 1H NMR (400 MHz, CDCl3), δ
7.78 (d, J = 5.5 Hz, 1H), 7.35 (d, J = 5.5 Hz, 1H), 3.96 (t, J = 6.5
Hz, 2H), 3.53 (s, 3H), 3.18 (s, 3H), 3.00 (t, J = 6.5 Hz, 2H), 2.55 (s,
3H).
Step 2: The product from Step 1 (230 mg, 0.9 mmol) was
dissolved in CH2Cl2 (10 mL) and treated with Et3N (73 μL, 1.0
mmol) followed by acetyl chloride (72 μL, 1.0 mmol). The reaction
was stirred at room temperature for 1 h and worked up by washing
the reaction mixture with sodium hydroxide solution (1 M, 10 mL)
followed by extraction of the aqueous layer with EtOAc (10 mL).
The combined organic layers were dried (Na2SO4), concentrated
under reduced pressure, and the crude residue was purified by flash
column chromatography (EtOAc/MeOH; 95:5 and then 90:10) to
give the product, N-(2-((2-chlorothieno[3,2-d]pyrimidin-4-yl)-
(methyl)amino)ethyl)-N-methylacetamide (IM9), as a low melting
solid (70 mg, 0.23 mmol, 26%). 1H NMR as a 3:1 mixture of
rotamers (400 MHz, CDCl3) δ 7.72 (d, J = 5.5 Hz, 0.3H), 7.69 (d, J
= 5.5 Hz, 0.7H), 7.22 (d, J = 5.5 Hz, 0.3H), 7.19 (d, J = 5.5 Hz,
0.7H), 3.82 (t, J = 6.0 Hz, 1.4H), 3.75 (dd, J = 8.3, 6.0 Hz, 0.6H),
3.56 (t, J = 6.0 Hz, 1.4H), 3.51 (dd, J = 8.3, 6.0 Hz, 0.6H), 3.44 (s,
0.9H), 3.42 (s, 2.1H), 3.02 (s, 2.1H), 2.92 (s, 0.9H), 2.06 (s, 0.9H),
1.85 (s, 2.1H).
3-((2-Chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)-N,N-di-
methylpropanamide (IM10). Using general method A, 2,4-
dichlorothieno[3,2-d]pyrimidine (205 mg, 1.0 mmol) was treated
with DIPEA (174 μL, 1.0 mmol) followed by N,N-dimethyl-3-
(methylamino)propanamide (170 mg, 1.5 mmol). After workup, the
Journal of Medicinal Chemistry pubs.acs.org/jmc Article
https://dx.doi.org/10.1021/acs.jmedchem.0c00570
J. Med. Chem. 2020, 63, 7740−7765
7760
residue was purified by flash column chromatography (EtOAc/
MeOH; 100:0 and then 95:5) to give the product, 3-((2-
chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)amino)-N,N-dimethyl-
propanamide (IM10), as a pale yellow solid. 1H NMR (400 MHz,
CDCl3) δ 7.78 (m, 1H), 7.41−7.32 (m, 1H), 4.10−4.03 (m, 2H),
3.57 (s, 3H), 3.11 (s, 3H), 2.98 (s, 3H), 2.83−2.76 (m, 2H).
(S)-(1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)-
methanol (IM11). Using general method A, 2,4-dichlorothieno[3,2-
d]pyrimidine (205 mg, 1.0 mmol) was treated with DIPEA (209 μL,
1.2 mmol) followed by (S)-pyrrolidin-2-ylmethanol (100 μL, 1.0
mmol). After workup, the crude residue was purified by column
chromatography (EtOAc/hexane; 50:50−100:0) to give the product,
(S)-(1-(2-chlorothieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)-
methanol (IM11), as a colorless solid (242 mg, 0.90 mmol, 90%).
Mp 160−161 °C; 1H NMR (400 MHz, CDCl3) δ 7.81 (d, J = 5.5
Hz, 1H), 7.33 (d, J = 5.5 Hz, 1H), 4.59 (dq, J = 7.0, 3.5 Hz, 1H),
4.10 (dd, J = 7.0, 4.5 Hz, 2H), 3.87 (dd, J = 11.5, 3.5 Hz, 1H), 3.79
(dd, J = 11.5, 7.0 Hz, 1H), 2.27−2.08 (m, 3H), 1.93 (td, J = 8.1, 7.0,
3.5 Hz, 1H).
(S)-2-Chloro-4-(2-(methoxymethyl)pyrrolidin-1-yl)thieno[3,2-d]-
pyrimidine (IM12). Using general method A, 2,4-dichlorothieno[3,2-
d]pyrimidine (205 mg, 1.0 mmol) was treated with DIPEA (209 μL,
1.2 mmol) followed by (S)-2-(methoxymethyl)pyrrolidine (123 μL,
1.0 mmol). After workup, the product, (S)-2-chloro-4-(2-
(methoxymethyl)pyrrolidin-1-yl)thieno[3,2-d]pyrimidine (IM12),
crystallized on evaporation of the solvent as a colorless solid (250
mg, 0.88 mmol, 88%). Mp 110−112 °C; 1H NMR (400 MHz,
CDCl3) δ 7.77 (d, J = 5.5 Hz, 1H), 7.35 (d, J = 5.5 Hz, 1H), 4.70
(td, J = 7.5, 3.0 Hz, 1H), 4.10−4.00 (m, 1H), 4.00−3.87 (m, 1H),
3.65 (dd, J = 9.5, 3.0 Hz, 1H), 3.63−3.53 (m, 1H), 3.40 (s, 3H),
2.32−2.13 (m, 2H), 2.13−2.01 (m, 2H).
(S)-2-(1-(2-Chlorothieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)-
acetonitrile (IM13). A solution of 2,4-dichlorothieno[3,2-d]-
pyrimidine (205 mg, 1.0 mmol, 1.0 equiv) in EtOAc (10 mL) was
treated with DIPEA (1.2 equiv) followed by (S)-2-(pyrrolidin-2-
yl)acetonitrile (125 mg, 1.1 mmol), and the reaction was heated
under reflux for 4 h. The reaction mixture was cooled to room
temperature and then washed with sodium hydroxide solution (1 M,
10 mL), and the aqueous layer was re-extracted with EtOAc (10
mL). The combined organic layers were dried (Na2SO4),
concentrated under reduced pressure, and the residue was purified
by flash column chromatography (DCM/hexane; 50:50−100:0 and
then DCM/MeOH; 95:5) to give the product, (S)-(1-(2-
chlorothieno[3,2-d]pyrimidin-4-yl)pyrrolidin-2-yl)methanol (IM13),
as a yellow solid (115 mg, 0.41 mmol, 41%). 1H NMR (400 MHz,
CDCl3) δ 7.82 (d, J = 5.5 Hz, 1H), 7.35 (d, J = 5.5 Hz, 1H), 4.68
(tt, J = 7.0, 3.5 Hz, 1H), 4.17 (ddd, J = 9.0, 7.5, 4.5 Hz, 1H), 4.07
(dt, J = 9.0, 7.5 Hz, 1H), 3.13 (dd, J = 16.8, 7.0 Hz, 1H), 2.93 (dd, J
= 16.8, 3.5 Hz, 1H), 2.48−2.23 (m, 2H), 2.17 (tdd, J = 10.9, 6.3, 3.5
Hz, 2H).
2-Chloro-N-ethyl-N-methylthieno[3,2-d]pyrimidin-4-amine
(IM14). Using general method A, 2,4-dichlorothieno[3,2-d]-
pyrimidine (307 mg, 1.5 mmol) was treated with DIPEA (313 μL,
1.8 mmol) followed by N-methylethanamine (128 μL, 1.5 mmol).
After workup, the product, 2-((2-chlorothieno[3,2-d]pyrimidin-4-
yl)(methyl)amino)ethanol (IM14), crystallized on evaporation of the
solvent as a pale yellow solid (305 mg, 1.3 mmol, 89%) with no need
for further purification. Mp 105−107 °C; 1H NMR (400 MHz,
CDCl3) δ 7.77 (d, J = 5.8 Hz, 1H), 7.37 (d, J = 5.8 Hz, 1H), 3.88 (q,
J = 7.1 Hz, 2H), 3.44 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H).
3-((6-(tert-Butyl)-2-chlorothieno[3,2-d]pyrimidin-4-yl)(methyl)-
amino)propanenitrile (IM15). To a solution of 6-(tert-butyl)-2,4-
dichlorothieno[3,2-d]pyrimidine (233 mg, 0.9 mmol, 1.0 equiv) in
DMF (2.0 mL) was added DIPEA (310 μL, 1.8 mmol, 2.0 equiv)
followed by 3-(methylamino)propanenitrile (167 μL, 1.8 mmol, 2.0
equiv), and the reaction was stirred at room temperature overnight.
The reaction mixture was washed with sodium hydroxide solution (1
M, 10 mL), and the aqueous layer was re-extracted with EtOAc (10
mL). The combined organic layers were dried (Na2SO4) and then
concentrated under reduced pressure. The crude product was
purified by flash column chromatography by elution with ethyl
acetate/hexane (2:1) giving the product (239 mg, 0.77 mmol, 86%).
3-((6-Bromo-2-chloroquinazolin-4-yl)(methyl)amino)-
propanenitrile (IM16). To a suspension of 6-bromo-2,4-dichlor-
oquinazoline (290 mg, 1.0 mmol) and 3-(methylamino)-
propanenitrile (195 μL, 2.1 mmol, 2.0 equiv) in DMF (3.0 mL)
was added DIPEA (363 μL, 2.1 mmol, 2.0 equiv), and the solution
was stirred at room temperature for 2 h. Water was added, and the
solid formed was isolated by filtration, washed with water, and dried
to give the product (156 mg, 0.48 mmol, 48%) as an orange powder.
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 2.0 Hz, 1H), 7.82 (dd, J
= 9.0, 2.0 Hz, 1H), 7.69 (d, J = 2.0 Hz, 1H), 4.04 (t, J = 6.4 Hz,
2H), 3.67 (s, 3H), 2.94 (t, J = 6.4 Hz, 3H).
3-((2-Chloro-6-methoxyquinazolin-4-yl)(methyl)amino)-
propanenitrile (IM17). To a suspension of 2,4-dichloro-6-methox-
yquinazoline (90 mg, 0.39 mmol, 1.0 equiv) and 3-(methylamino)-
propanenitrile (74 μL, 0.8 mmol, 2.0 equiv) in DMF (1.0 mL) was
added DIPEA (137 μL, 0.8 mmol, 2.0 equiv), and the solution was
stirred at room temperature for 2 h. Water was added, and the solid
formed was isolated by filtration, washed with water, and dried to
give the product (50 mg, 46%) as a yellow powder. 1H NMR (400
MHz, CDCl3) δ 7.80 (d, J = 9.2 Hz, 1H), 7.43 (dd, J = 9.2, 2.7 Hz,
1H), 7.36 (d, J = 2.7 Hz, 1H), 4.00 (t, J = 6.5 Hz, 2H), 3.91 (s, 3H),
3.61 (s, 3H), 2.94 (t, J = 6.5 Hz, 2H).
3-((2-Chloro-6-phenylquinazolin-4-yl)(methyl)amino)-
propanenitrile (IM18). 3-((6-Bromo-2-chloroquinazolin-4-yl)-
(methyl)amino)propanenitrile (25 mg, 0.08 mmol, 1.0 equiv) and
phenyl boronic acid (9.4 mg, 0.08 mmol, 1.0 equiv) were dissolved in
DMF (1.0 mL), and Pd(OAc)2 (1.0 mg, 0.004 mmol, 0.05 equiv)
was added. A solution of Cs2CO3 (50 mg, 0.15 mmol) in H2O (0.3
mL) was added and stirred at room temperature for 2 h. The
solution was diluted with EtOAc (15 mL) and then washed with
H2O (5 × 10 mL) and then brine (10 mL) before drying over
MgSO4. The compound was purified by flash column chromatog-
raphy (EtOAc/hexane 5:95−30:70) to give the product as a white
solid (10 mg, 43%). 1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 1.9
Hz, 1H), 8.00 (dd, J = 8.7, 1.9 Hz, 1H), 7.91 (d, J = 8.7 Hz, 1H),
7.65−7.57 (m, 2H), 7.55−7.46 (m, 2H), 7.46−7.38 (m, 1H), 4.08 (t,
J = 6.5 Hz, 2H), 3.72 (s, 3H), 2.97 (t, J = 6.5 Hz, 2H).
3-((2-Chloro-6-phenylquinazolin-4-yl)(methyl)amino)-
propanenitrile (IM19). 3-((6-Bromo-2-chloroquinazolin-4-yl)-
(methyl)amino)propanenitrile (50 mg, 0.15 mmol, 1.0 equiv) and
2-methylphenyl boronic acid (21 mg, 0.15 mmol, 1.0 equiv) were
dissolved in DMF (2.0 mL), and Pd(OAc)2 (2.0 mg, 0.008 mmol,
0.05 equiv) was added. A solution of Cs2CO3 (100 mg, 0.31 mmol)
in H2O (0.6 mL) was added, and the solution was stirred at room
temperature for 2 h. The solution was diluted with EtOAc (15 mL)
and then washed with H2O (5 × 10 mL) and then brine (10 mL)
before drying over MgSO4. The compound was purified by flash
column chromatography (EtOAc/hexane 5:95−30:70) to give a
colorless oil (34 mg, 0.10 mmol, 67%). 1H NMR (400 MHz, CDCl3)
δ 8.00 (d, J = 1.8 Hz, 1H), 7.87 (d, J = 8.6 Hz, 1H), 7.74 (dd, J =
8.6, 1.8 Hz, 1H), 7.38−7.21 (m, 4H), 4.05 (t, J = 6.5 Hz, 2H), 3.65
(s, 3H), 2.96 (t, J = 6.5 Hz, 2H), 2.29 (s, 3H).
3-((2-Chloro-6-(4-methoxy-2-methylphenyl)quinazolin-4-yl)-
(methyl)amino)propanenitrile (IM20). 3-((6-Bromo-2-chloroquina-
zolin-4-yl)(methyl)amino)propanenitrile (50 mg, 0.15 mmol, 1.0
equiv) and (4-methoxy-2-methylphenyl)boronic acid (25 mg, 0.15
mmol, 1.0 equiv) were dissolved in DMF (2.0 mL), and Pd(OAc)2
(2.0 mg, 0.009 mmol, 0.06 equiv) was added. A solution of Cs2CO3
(100 mg, 0.31 mmol) in H2O (0.6 mL) was added, and the solution
was stirred at room temperature for 2 h. The solution was diluted
with EtOAc (15 mL) and then washed with H2O (5 × 10 mL) and
then brine (10 mL) before drying over MgSO4. The compound was
purified by flash column chromatography (EtOAc/hexane 5:95−
25:75) to give a white solid (22 mg, 0.06 mmol, 40%). 1H NMR
(400 MHz, CDCl3) δ 7.96 (dd, J = 1.8, 0.6 Hz, 1H), 7.84 (dd, J =
8.6, 0.6 Hz, 1H), 7.71 (dd, J = 8.6, 1.9 Hz, 1H), 7.18 (d, J = 8.3 Hz,
1H), 6.89−6.80 (m, 2H), 4.04 (t, J = 6.5 Hz, 2H), 3.85 (s, 3H), 3.64
(s, 3H), 2.95 (t, J = 6.5 Hz, 2H), 2.28 (s, 3H).
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3-((2-Chloro-7-methoxyquinazolin-4-yl)(methyl)amino)-
propanenitrile (IM21). To a suspension of 2,4-dichloro-7-methox-
yquinazoline (30 mg, 0.13 mmol, 1.0 equiv) and 3-(methylamino)-
propanenitrile (25 μL, 0.26 mmol, 2.0 equiv) in DMF (0.5 mL) was
added DIPEA (46 μL, 0.26 mmol, 2.0 equiv), and the solution was
stirred at room temperature for 2 h. Water was added, and the solid
formed was isolated by filtration, washed with water, and dried to
give the product (10 mg, 0.036 mmol, 28%) as a white solid. 1H
NMR (400 MHz, CDCl3) δ 7.98 (d, J = 9.3 Hz, 1H), 7.18 (d, J = 2.7
Hz, 1H), 7.04 (dd, J = 9.4, 2.7 Hz, 1H), 4.02 (t, J = 6.5 Hz, 2H),
3.92 (s, 3H), 3.62 (s, 3H), 2.93 (t, J = 6.5 Hz, 2H).
3-((2-Chloropyrimidin-4-yl)(methyl)amino)propanenitrile
(IM22). 3-(Methylamino)propanenitrile (571 μL, 6.7 mmol, 2.0
equiv) was added to a solution of 2,4-dichloropyrimidine (500 mg,
3.4 mmol, 1.0 equiv) and DIPEA (1.2 mL, 6.7 mmol, 2.0 equiv) in
DMF (5.0 mL) and stirred at room temperature for 2 h. The
solution was diluted with water and then extracted with EtOAc. The
compound was purified by flash column chromatography (EtOAc/
hexane 1:4) to give a solid (200 mg, 1.0 mmol 15%). 1H NMR (400
MHz, CDCl3)
1H NMR (400 MHz, chloroform-d) δ 8.13 (d, J = 6.1
Hz, 1H), 6.40 (d, J = 6.1 Hz, 1H), 3.91 (t, J = 6.4 Hz, 2H), 3.20 (s,
3H), 2.75 (t, J = 6.4 Hz, 2H).
Biochemical Methods. Protein Production and Crystallog-
raphy. Protein production and crystallization of LmNMT-MyrCoA
were as described in Brannigan et al. (2014).30 Ligand compounds
(25 mM stocks in 50% dimethyl sulfoxide, DMSO) were used at a
final concentration of 2.5 mM to soak LmNMT-MyrCoA crystals. X-
ray diffraction data were collected on synchrotron beamlines at the
Diamond Light Source (Didcot, U.K.) and processed using XDS42
and SCALA43 implemented within xia2.44 Data collection and
refinement statistics are summarized in Table S3. For Rfree
calculations, 5% of the data were excluded. Cycles of refinement
using maximum-likelihood methods implemented in REFMAC45
were interspersed with model building and adjustment using
COOT.46 The final refined protein structure models display good
geometry with typically only a single amino acid residue (His347)
lying outside of the preferred region of the Ramachandran plot.
CPM Assay. The enzyme-based inhibitory potency of all
derivatives was determined for LdNMT, LmNMT, and HsNMT1
using the CPM assay format, as described previously.31,32 Data is
summarized in Table S1, and the dose−response curves are shown in
Figures S6−S8.
Alamar Blue-Based Assay. The assay was conducted as previously
described and validated using amphotericin B and miltefosine as
reference compounds. An Ethiopian strain of L. donovani (MHOM/
ET/67/HU3, also known as LV9) was maintained in Rag-2−/− mice
by serial passage. All experiments were approved by the University of
York Animal Procedures and Ethics Committee and performed under
the U.K. Home Office licence (“Immunology and Immunopathology
of Leishmaniasis” Ref # PPL 60/4377). Isolation of amastigotes from
infected spleens was performed by saponin lysis after homoge-
nization, as previously described.37 Afterward, Ld amastigotes were
plated at 4 × 105 parasites per well in 96-well plates followed by the
addition of the inhibitor concentrations in RPMI medium
supplemented with 20% heat-inactivated fetal calf serum (FCS),
100 μM adenine, 20 mM 2-[N-morpholino] ethanesulfonic acid (pH
5.5), 5 μM hemin, 3 μM biopterin, 1 μM biotin, penicillin (100 U/
mL), and streptomycin (100 μg/mL). After 72 h at 26 °C, 1/5
volume Alamar blue (Trek Diagnostics) was added. Fluorescence was
measured after another 6 h using a POLARstar Optima (BMG
Labtech) plate reader (ex. 544 nm, em. 590 nm).
Macrophages (BMDM) were differentiated from the bone marrow
of 6−8 week old female BALB/c mice, as described previously,37 and
maintained at 37 °C and 5% CO2 in DMEM (GIBCO)
supplemented with 4 mM L-glutamine (GIBCO) and 4% L929-
cell-conditioned medium. BMDMs were seeded at 4.2 × 104 cells per
well in 96-well plates and adhered for at least 4 h. Subsequently,
inhibitor concentrations were added for 72 h, followed by the
addition of a 1/10 volume Alamar blue (Trek Diagnostics).
Fluorescence was measured after 6 h as described above. Data is
summarized in Table S2, and the dose−response curves are shown in
Figures S9 and S10.
Tagging Assay. Freshly isolated amastigotes (see above) were
seeded at 7.5 × 107 parasites per mL and cultured in RPMI
supplemented with 10% FCS and the corresponding inhibitor
concentration. After 1 h at 37 °C, the parasites were collected by
centrifugation (800g, 15 min, 4 °C) and resuspended in a fresh
medium containing the inhibitor dilution and YnMyr or myristic acid
(final concentration 50 μM). After 12 h, the parasites were pelleted
and washed twice with cold phosphate-buffered saline (PBS).
Subsequently, the cells were lysed on ice at 1 × 109 parasites per
mL in lysis buffer (1% NP40, 1% sodium deoxycholate, 0.5% sodium
dodecyl sulfate (SDS), 50 mM Tris (pH 7.4), 150 mM NaCl, EDTA-
free protease inhibitor) by sonication (4 × 10 second burst,
amplitude 45 with 1 min interval). All lysates were cleared by
centrifugation (16 100g, 30 min, 4 °C), and protein concentrations
were determined using the DC Protein Assay (Bio-Rad) following
the manufacturer’s procedure.
Proteins were precipitated with chloroform/methanol (MeOH/
CHCl3/H2O 4:1:3) and resuspended at 1 mg/mL in 1% SDS in PBS.
Afterward, 1 μL AzTB41 (10 mM in DMSO, 0.1 mM final), 2 μL
CuSO4 (50 mM in H2O, 1 mM final), 2 μL Tris(2 carboxyethyl)-
phosphine hydrochloride (TCEP) (50 mM in H2O, 1 mM final), and
1 μL Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (10
mM in DMSO, 0.1 mM final) were mixed. Six microliters of this
click mixture was added to 100 μL of lysate, and the click reaction
was shaken for 1 h at room temperature. Subsequently, the proteins
were precipitated again by methanol/chloroform precipitation. The
protein pellet was air-dried and redissolved in PBS containing 0.2%
SDS and 0.1 mM dithiothreitol (DTT) using sonication to a final
protein concentration of 1 mg/mL. All samples were further analyzed
by SDS-PAGE, and fluorescence was scanned using a Typhoon
imager (GE Healthcare; excitation laser: 532 nm, emission filter:
LPG (575−700 nm); PMT: 750 V). For Western blot, the proteins
were transferred from gels to poly(vinylidene fluoride) membranes
(Immobilon-PSQ, Millipore) using a semidry system (Invitrogen).
Following blocking (5% milk in TBS-T buffer), the membranes were
incubated for 1 h at room temperature with the primary and
overnight at 4 °C with the secondary HRP-conjugated antibody.
Detection was performed using a Luminata Crescendo Western HRP
substrate (Millipore) according to the manufacturer’s instructions
with a Fujifilm LAS 3000 imager.
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